Method of diagnosing integration dysfunction syndrome using blood

ABSTRACT

An object of the present invention is. to provide an objective method for diagnosis of schizophrenia using gene expression in mononuclear cells of peripheral blood as an index, and this invention provide a method for diagnosing whether a test subject suffers from schizophrenia or not. The method according to this invention is a method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing nucleic acid from said subject, measuring the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and determining alteration of the quantified level(s) of the gene(s) in said test subject is statistically significant in comparison with the quantified level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or schizophrenic patients, thereby diagnosing whether said subject is suffering from schizophrenia or not.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to an objective method for diagnosis of schizophrenia using gene expression in blood as an index.

2. Prior Art

Schizophrenia is a mental disorder and about 0.8% of the population suffers from schizophrenia during their youth. For it takes a long time to recover from schizophrenia, social loss caused by schizophrenia is immensely large. Therefore, enthusiastic investigations have been made in many laboratories all over the world to develop therapies and diagnoses for schizophrenia. In particular, significant progress has been made on therapies since development of dopamine receptor antagonists such as chlorpromazine. In contrast, diagnosis of schizophrenia is still classified based on psychological symptoms such as paranoid type, disorganized type, catatonic type and a type incapable to be classified, even in the latest US diagnostic reference “DSMIV”. Therefore, diagnosis of schizophrenia finally relies upon subjective diagnosis made by the doctor in attendance, hence, diagnostic accuracy of schizophrenia has not been sufficient. Under such circumstances, chromosomal mapping of gene responsible for schizophrenia and identification of the gene have been made enthusiastically. However, definitive reports have been not made on such gene yet.

In occurrence of schizophrenia, it is known that considerable genetic backgrounds are underlying as risk factors. According to recent progress in genetic analysis, it is revealed that plural genes are involved in schizophrenia (Chiu Y F et al., Mol Psychiatry, 2002; 7(6): 658-664; Reference 1). Moreover, from above-mentioned pathognomy, the disease itself is considered to be a complex disease comprising plural disorders (Kirkpatrick B et al., Arch Gen Psychiatry, 2001; 58(2): 165-171; Reference 2).

Recently, it has been recognized that schizophrenia is not only a local disease involved in cerebral nerve system, but a systemic disease involved in immune system etc. Actually, it has been revealed that components of peripheral serum such as epidermal growth factor (Nawa H et al., Mol Psychiatry, 2002; 7(7): 673-682; Reference 3), brain-derived neurotrophic factor (Nawa H et al., Mol Psychiatry, 2002; 110(3): 249-257; Reference 4) and interleukin-8 (Akiyama et al., Schizophr Res., 1995; 37(1): 97-106; Reference 5) exhibit alteration in their expression levels in accordance with occurrence of the disease. Therefore, though patent properties on theses components have been acquired as a diagnostic method for the disease, the accuracy of determination remained to be low.

Moreover, as prior references concerning pathologic diagnosis by multi-measurement using a DNA micro-array or a DNA chip, references of following (6), (7) and (8) can be listed. In addition, literatures on analysis using brain tissue (not using peripheral blood like this invention) by a DNA micro-array or a DNA chip, references of following (9) and (10) can be listed. Furthermore, as prior arts involved in diagnosis of schizophrenia using proteins in blood, references of following (11), (12) and (13) can be listed. Furthermore, in addition to above-mentioned references, Patent Publication No.JP 2001-235470, Patent Publication JP 2001-245661, Patent Application JP 2000-331742, Patent Application JP 2001-228038 (Patent Publication JP 2003-038198) and Patent Application JP 2002-036937 (Patent Publication JP 2003-235557) can be listed.

REFERENCE LIST

-   (1) Chiu Y F et al., Mol Psychiatry, 2002; 7(6): 658-664. -   (2) Kirkpatrick B et al., Arch Gen Psychiatry, 2001; 58(2): 165-171. -   (3) Nawa H et al., Mol Psychiatry, 2002; 7(7): 673-682. -   (4) Nawa H et al., Mol Psychiatry, 2002; 110(3): 249-257. -   (5) Akiyama et al., Schizophr Res., 1995; 37(1): 97-106. -   (6) Bertucci F, Viens P, Hingamp P, Nasser V, Houlgatte R, Birnbaum     D., Int. J Cancer. 2003; 103(5): 565-571. -   (7) Staudt L M. N. Engl. J. Med., 2003; 348(18): 1777-1785 -   (8) Bertucci F, Houlgatte R, Nguyen C, Viens P, Jordan B R, Birnbaum     D., Lancet Oncol. 2001; 2(11): 674-682. -   (9) Hakak, Y. et al., Proc Natl Acad Sci USA. 2001; 98: 4746-4751 -   (10) Mirnics, K. et al., Neuron. 2000; 28: 53-67. -   (11) Toyooka, K. et al. Neurosci Res., 2003; 46: 299-307. -   (12) Futamura, T. et al. Mol Psychiatry., 2002; 7: 673-682. -   (13) Toyooka, K. et al. Psychiatry Res., 2002; 110: 249-257.

SUMMARY OF THE INVENTION

The present invention was performed to solve aforementioned problems. An object of the present invention is to provide a reliable method for diagnosis of schizophrenia using small amount of blood as a sample, without forcing risk or pain to a patient.

To solve said problems, the present invention provides a method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of;

-   -   obtaining mononuclear cells in blood containing nucleic acid         from said subject,     -   measuring the content of at least one nucleic acid selected from         the group consisting of nucleic acid(s) (containing its fragment         and a nucleic acid complementary to the nucleic acid) defining         gene(s) exhibiting altered expression by occurrence of         schizophrenia or nucleic acid(s) (containing its fragment and a         nucleic acid complementary to the nucleic acid) defining gene(s)         exhibiting altered expression by progression of schizophrenia in         said mononuclear cells, and     -   determining alteration of the quantified level(s) of the gene(s)         in said test subject is statistically significant in comparison         with the quantified level(s) of said nucleic acid(s) defining         gene(s) exhibiting altered expression by occurrence of         schizophrenia or said nucleic acid(s) defining gene(s)         exhibiting altered expression by progression of schizophrenia in         healthy subjects or schizophrenic patients, thereby diagnosing         whether said subject is suffering from schizophrenia or not.

Moreover, the present invention provides a method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of;

-   -   obtaining protein derived from mononuclear cells in blood from         said test subject,     -   measuring the content of at least one protein selected from the         group consisting of protein(s) (containing its fragment) encoded         by nucleic acid(s) defining gene(s) exhibiting altered         expression by occurrence of schizophrenia or protein(s)         (containing its fragment) encoded by nucleic acid(s) defining         gene(s) exhibiting altered expression by progression of         schizophrenia in said mononuclear cells, and     -   determining alteration of the quantified level of the protein(s)         in said test subject is statistically significant in comparison         with the quantified level(s) of said protein(s) encoded by         nucleic acid(s) defining gene(s) exhibiting altered expression         by occurrence of schizophrenia or said protein(s) encoded by         nucleic acid(s) defining gene(s) exhibiting altered expression         by progression of schizophrenia in healthy subjects or         schizophrenic patients, thereby diagnosing whether said subject         is suffering from schizophrenia or not.

According to the method of this invention, one can diagnose whether a test subject suffers from schizophrenia or not objectively without invasion. The method according to present invention provides a scientific and reliable method compared with conventional subjective methods for diagnosis of schizophrenia, and reinforces conventional diagnostic methods based on psychological symptoms.

Hereafter, the present invention is explained in detail. However, these detailed description of preferred embodiments and examples do not mean any restriction or limitation of the scope of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a figure showing distribution of healthy subjects, chronic patients and acute patients in the Mahalanobis cluster analysis.

FIG. 2 is a graph showing the discrimination points analyzed by mRNA levels of kinases/phoaphatases.

FIG. 3 is a graph showing the result of Mahalanobis cluster analysis using kinases/phoaphatases.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The present invention was achieved based on the knowledge obtained by the present inventors that the mRNA expression levels of 132 kinds of genes listed in Table 1 described below are altered by occurrence of schizophrenia with statistical significance. Moreover, mRNAs expression levels of 34 kinds of genes listed in Table 2 described below are altered by progression of schizophrenia with statistical significance. As described in detail in the following examples, the present inventors found 152 genes exhibiting altered expression accompanied with this disease, by comparing the expression levels of about 12000 kinds of genes from peripheral mononuclear cells from acute and chronic schizophrenic patients in hospital with those from normal individuals. Moreover, statistical values measured on these genes are shown in Table 3 described below.

Moreover, among genes listed in Table 1, 24 genes exhibited altered expression in acute non-treated acute schizophrenic patients compared with normal individuals. Furthermore, 111 genes exhibited altered expression in chronic schizophrenic patients in hospital. Meanwhile, 3 genes exhibited altered expression in both patient groups redundantly.

Incidentally, “nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia” in this specification means nucleic acid(s) described in Table 1, that is defined by the gene name, the protein name which is a gene product and the nucleic acid sequence name, as well as GenBank Accession Nos. described with the names. Among the genes listed in Table 1, No.1 to No.99 and No.129 to No.132 are included in a group of genes exhibiting decreased expression by schizophrenia. Whereas, among the genes listed in Table 1, No.99 to No.128 are included in a group of genes exhibiting increased expression by schizophrenia.

Furthermore, “nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia” in this specification means nucleic acid(s) described in Table 2, that is defined by the gene name, the protein name which is s gene product and the nucleic acid sequence name, as well as GenBank Accession Nos. described with the names. As described in the following Example, the genes described in Table 1 and Table 2 consisting of 152 genes in total are useful for the purpose of the invention to diagnose schizophrenia. Meanwhile, statistical values of the 152 genes described in Tables 1 and 2 are disclosed in Table 3, and the genes attached with the mark “NS” in Table 3 are those exhibiting altered expression by progression of schizophrenia and corresponds to genes listed in Table 3.

The method according to this invention is also useful for diagnose whether or not a test animal other than human, especially mammals, suffers from schizophrenia. In the following, a test animal means an animal other than human being, preferably mammals.

That is, this invention also provides a method for diagnosing whether a test animal suffers from schizophrenia or not, the method comprising the steps of;

-   -   obtaining mononuclear cells in blood containing nucleic acid         from said test animal,     -   measuring the content of at least one nucleic acid selected from         the group consisting of nucleic acid(s) (containing its fragment         and a nucleic acid complementary to the nucleic acid) defining         gene(s) exhibiting altered expression by occurrence of         schizophrenia or nucleic acid(s) (containing its fragment and a         nucleic acid complementary to the nucleic acid) defining gene(s)         exhibiting altered expression by progression of schizophrenia in         said mononuclear cells, and     -   determining alteration of the quantified level(s) of the gene(s)         in said test animal is statistically significant in comparison         with the quantified level(s) of said nucleic acid(s) defining         gene(s) exhibiting altered expression by occurrence of         schizophrenia or said nucleic acid(s) defining gene(s)         exhibiting altered expression by progression of schizophrenia in         healthy animals or schizophrenic animals, thereby diagnosing         whether said animal is suffering from schizophrenia or not.

Moreover, this invention provides a method for diagnosing whether a test animal suffers from schizophrenia or not, the method comprising the steps of;

-   -   obtaining protein derived from mononuclear cells in blood from         said test animal,     -   measuring the content of at least one protein selected from the         group consisting of protein(s) (containing its fragment) encoded         by nucleic acid(s) defining gene(s) exhibiting altered         expression by occurrence of schizophrenia or protein(s)         (containing its fragment) encoded by nucleic acid(s) defining         gene(s) exhibiting altered expression by progression of         schizophrenia in said mononuclear cells, and

determining alteration of the quantified level of the protein(s) in said test animal is statistically significant in comparison with the quantified level(s) of said protein(s) encoded by nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said protein(s) encoded by nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy animals or schizophrenic animals, thereby diagnosing whether said animal is suffering from schizophrenia or not. TABLE 1 No. Genbank Gene Name 1 AI677689 Homo sapiens cDNA, 3 end/clone = IMAGE-2329930, EST wd33c06.x1 2 Z23115 Bcl-X1 3 X69115 ZNF37A mRNA for zinc finger 4 X07024 HSCCG1 Human X chromsome mRNA for CCG1 protein inv.in cell proliferation 5 L42243 Interferon receptor, alternatively spliced interferon receptor (IFNAR2) 6 HG960-HT960 Guanine Nucleotide Exchange Factor 1 7 Z12173 Glucosamine-6-sulphatase precursor 8 X98176 MACH-beta-1 protein (Caspase 8) 9 W25921 15a11 Homo sapiens cDNA/gb = W25921/gi = 1306044/ ug = Hs.164036/len = 723 10 Z35102 Ndr protein kinase 11 U28964 14-3-3 protein 12 X74262 RbAp48 mRNA encoding retinoblastoma binding protein 13 Y09568 SNAP23B protein 14 AF038960 SKD1 homolog 15 AI955897 Homo sapiens cDNA, 3 end/clone = IMAGE-2509049 ETS wt31b09.x1 16 X69086 Utrophin 17 M80629 Cdc2-related protein kinase (CHED) 18 U12022 Calmodulin type 1 (CALM1) 19 X74594 Rb2/p130 protein 20 M64174 Protein-tyrosine kinase JAK1 21 M28212 GTP-binding protein RAB6 22 U94333 Clq/MBL/SPA receptor C1qR(p) 23 U13948 Zinc finger/leucine zipper protein (AF10) 24 U96919 Inositol polyphosphate 4-phosphatase type I-beta 25 U26398 Inositol polyphosphate 4-phosphatase 26 AF068836 Cytohesin binding protein HE 27 L43821 CAS like protein for enhancer of filamentation (HEF1) 28 U17032 Rho GTPase activated protein type 5 (p190-B) 29 AB022017 AMP-activated protein kinase alpha-1 30 AF038897 Syntaxin 16 31 HG846-HT846 Cyclophilin-Related Protein 32 L04288 Natural killer-tumor recognition sequence 33 S66213 Integrin alpha 6B (CD49f) 34 AF052160 Homo sapiens clone 24629 mRNA sequence 35 AB015982 Protein kinase C Nu (EPK2), EPK2 mRNA for serine/threonine kinase 36 S79325 mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585 nt], [synovial sarcomas, mRNA Partial Mutant, 3 genes, 585 nt] 37 M55536 Glucose transporter pseudogene 38 X97674 Nuclear receptor intermediary activation factor 2 (TIF2), transcriptional intermediary factor 2 39 U16028 CRE-BP1 transcription factor 40 M27504 Topoisomerase type II beta (Topo II) 41 U13044 Nuclear respiratory factor-2 subunit alpha 42 AC004990 PAC clone DJ1185I07 from 7q11.23-q21 43 AF048732 Cyclin T2b 44 AF061261 Zinc finger protein type C3H (MBLL) 45 U29671 MEK kinase (Mekk) 46 AB023967 Rod1 47 U07794 HSTXK Human tyrosine kinase (TXK) 48 U48736 Serine/threonine-protein kinase PRP4h (PRP4h) 49 AJ001810 Pre-mRNA cleavage factor I subunit Im 50 AI961669 Homo sapiens cDNA, 3 end/clone = IMAGE-2512364 EST wt65e11x1 51 Z48579 Disintegrin-metalloprotease 52 AF047432 ADP-ribosylation factor no.6 (ARF6) 53 U50553 Helicase like protein 2 containing DEAD/H box, helicase like protein 2 (DDX14) 54 U57317 P300/CBP-associated factor (P/CAF) 55 U08316 Ribosomal protein S6 kinase, insulin-stimulated protein kinase 1 (ISPK-1) 56 X77794 Cyclin G1 57 U43083 Guanine binding protein type q, G alpha-q (Gaq) 58 AF094481 Trinucleotide repeat CGG-DNA binding protein p20- CGGBP (CGGBP) 59 L12002 Integrin alpha 4 subunit 60 AB002450 Chromosome 5q21-22, clone-A3-A 61 X77723 Unknown protein of uterine endometrium 62 M97935 Transcription factor ISGF-3 (STAT91) 63 AC002086 Human PAC clone DJ525N14 from Xq23 64 AF100539 SH2 domain protein 1A isoform B (SH2D1A) 65 AJ001683 Killer cell lectin-like receptor NKG2F (NKG2F) 66 U13896 Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) 67 U57452 Human SNF1-like protein kinase 68 X14798 Human DNA for c-ets-1 proto-oncogene 69 D16815 EAR-1r 70 L22075 Guanine nucleotide regulatory protein (G alpha 13) 71 L49229 Retinoblastoma susceptibility protein (RB1) 72 D13540 SH-PTP3 for protein-tyrosine phosphatase 73 W25874 EST 14e9 Homo sapiens cDNA 74 AF007111 MDM2-like p53-binding protein (MDMX) 75 AA013087 Homo sapiens cDNA, 5 end/clone = IMAGE-360208 EST ze27c09.r1 76 J04101 Erythroblastosis virus oncogene homolog 1 (ets-1) 77 X74837 HUMM9, Man9-mannosidase alpha, class 1A 78 X65873 Kinesin heavy chain 5B 79 U50648 Interferon-inducible RNA-dependent protein kinase (Pkr) 80 X15949 Interferon regulatory factor-2 (IRF-2) 81 AI189226 Homo sapiens cDNA, 3 end/clone = IMAGE-1722789 EST qd04h11.x1 82 D32039 Chondroitin sulfate proteoglycan PG-M (bursicon), proteoglycan PG-M(V3) 83 AL049962 Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) 84 W27675 36b3 Homo sapiens cDNA 85 AW006742 Homo sapiens cDNA, 3 end/clone = IMAGE-2489058 EST wr28g10.x1 86 AA457029 Homo sapiens cDNA, 3 end/clone = IMAGE-815515 EST aa 38b10.s1 87 J03069 c-myc proto-oncogene (MYCL2) 88 Z24459 Mature T cell proliferation factor c6.1B gene; MTCP1 gene 89 AB018340 Homo sapiens mRNA for KIAA0797 protein 90 X02751 N-ras 91 U94747 WD repeat protein HAN11 92 AB028971 Homo sapiens mRNA for KIAA1048 protein 93 AB007923 Homo sapiens mRNA for KIAA0454 protein 94 AB026891 Cystine/glutamate transporter 95 U04735 Microsomal stress 70 protein ATPase core (stch) 96 X07767 cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) 97 AA058762 Homo sapiens cDNA, 5 end/clone = IMAGE-487691 98 M69177 Monoamine oxidase B (MAOB) 99 M20560 Lipocortin-III (annexins A3) 100 AB007977 Homo sapiens chromosome 1 specific transcript KIAA0508 101 D10202 Platelet-activating factor receptor 102 AL048308 DKFZp586A2224_s1 Homo sapiens cDNA 103 X66363 PCTAIRE-1 for serine/threonine protein kinase 104 M94345 Gelsolin; macrophage capping protein; villin 105 W27466 31c9 Homo sapiens cDNA 106 Y15909 Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) 107 X02160 Insulin receptor precursor 108 L41827 Heregulin type 1; sensory and motor neuron-derived factor (HRG alpha) 109 AF026548 Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) 110 X71129 Electron transfer flavoprotein beta subunit 111 U88153 P160 112 U08015 Calciceurin dependently activated T cell nuclear factor (NF-Atc) 113 AB011135 Homo sapiens mRNA for KIAA0563 protein 114 X13839 Vascular smooth muscle alpha-actin 115 AF076838 Rad17-like protein (RAD17) 116 AI762213 Homo sapiens cDNA, 3 end/clone = IMAGE-2394055 EST wi54d04.x1 117 L77213 Phosphomevalonate kinase 118 D17530 Drebrin E 119 D64109 Tob family transducer ERBB2,2 120 AB016816 MASL1 121 AB023211 Homo sapiens mRNA for KIAA0994 protein 122 AA521060 Homo sapiens cDNA, 3 end/clone = IMAGE-826408 EST aa71e09.s1 123 X77094 Neutrophil cytoplasmic factor type 4 (P40phox) 124 HG2689-HT2785 Mucin 5b, Tracheobronchial 125 AC004893 Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 126 AB028973 Homo sapiens mRNA for KIAA1050 protein 127 AI148772 Homo sapiens cDNA, 3 end/clone = IMAGE-1714897 EST qc69b01.x1 128 AL109724 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 129 L12691 Defensins alpha 3 (neutrophil peptide-3) 130 M34379 Elastase/medullasin 131 AF002224 Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) 132 X69089 Skeletal muscle 165 kD protein

TABLE 2 No. Genbank Gene name 1 AI677689 Homo sapiens cDNA, 3 end/clone = IMAGE-2329930, EST wd33c06.x1 2 X74837 HUMM9, Man9-mannosidase alpha, class1A 3 D32039 Chondroitin sulfate proteoglycan PG-M (bursicon), proteoglycan PG-M(V3) 4 Z24459 Mature T cell proliferation factor c6.1B gene; MTCP1 gene 5 X07767 cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) 6 AW003733 Homo sapiens cDNA, 3 end/clone = IMAGE-2497327 7 M20560 Lipocortin-III (annexins A3) 8 X66363 PCTAIRE-1 for serine/threonine protein kinase 9 AI762213 Homo sapiens cDNA, 3 end/clone = IMAGE-2394055 EST wi54d04.x1 10 AA522537 Homo sapiens cDNA, 3 end/clone = IMAGE-979142 EST ni38e08.s1 11 U66359 Human T54 protein (T54) 12 Z80345 acyl-CoA dehydrogenase; SCAD gene 13 D17530 Drebrin E 14 L36645 Receptor protein-tyrosine kinase EphA4 (HEK8) 15 D64109 Tob family transducer BRBB2,2 16 AI039144 Homo sapiens cDNA, 3 end/clone = IMAGE-1657913 EST ox31b09.s1 17 AF000573 Homogentisate 1,2-dioxygenase 18 AB016816 MASL1 19 AA528252 Homo sapiens cDNA, 3 end/clone = IMAGE-965972 EST nh92c11.s1 20 M14648 Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) 21 AL049435 Cluster Incl AL049435: Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220) 22 L40392 Homo sapiens (clone S164) mRNA, 3 end of cds/cds 23 AB023226 Homo sapiens mRNA for KIAA1009 protein 24 AB018259 Homo sapiens mRNA for KIAA0716 protein 25 AJ132099 Vanin-like gene; vnn1 gene; VNN1 protein 26 AC004893 Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 27 AF001549 Human Chromosome 16 BAC clone CIT987SK-A-270G1 28 X55544 Transcriptional factor TREB protein 29 AB011120 Homo sapiens mRNA for KIAA0548 protein 30 U01877 P300; transcriptional adaptor protein; E1A-binding protein 31 L25851 Integrin alpha E precursor (CD103) 32 AI148772 Homo sapiens cDNA, 3 end/clone = IMAGE-1714897 EST qc69h01.x1 33 L12691 Defensins alpha 3 (neutrophil peptide-3) 34 AL036554 Homo sapiens cDNA, 5 end/clone = DKFZp564J2262.1

TABLE 3 Threshold Threshold of healthy of patient Healthy subject group Patient group group subject group 5% 1% Mean Standard 5% No. Genbank Mean S.D. threshold threshold vaue deviation threshold  1 AI677689 decrease 1.12 0.81 −0.18 −0.76 0.92 0.61 1.90  2 Z23115 decrease 1.72 0.93 0.23 −0.44 0.82 0.79 2.08  3 X69115 decrease 2.19 1.20 0.27 −0.60 1.07 1.18 2.96  4 X07024 decrease 1.64 0.74 0.46 −0.07 0.76 0.44 1.47  5 L42243 decrease 1.61 0.62 0.62 0.17 0.83 0.35 1.39  6 HG960-HT960 decrease 1.53 0.48 0.75 0.40 0.79 0.48 1.55  7 Z12173 decrease 1.97 0.77 0.75 0.19 0.85 0.60 1.82  8 X98176 decrease 1.83 0.58 0.91 0.49 0.80 0.53 1.64  9 W25921 decrease 1.48 0.47 0.74 0.40 0.81 0.43 1.51 10 Z35102 decrease 1.53 0.36 0.95 0.69 0.80 0.36 1.37 11 U28964 decrease 1.57 0.51 0.75 0.38 0.84 0.33 1.36 12 X74262 decrease 1.47 0.45 0.75 0.43 0.83 0.39 1.45 13 Y09568 decrease 1.56 0.41 0.91 0.62 0.86 0.41 1.51 14 AF038960 decrease 1.61 0.60 0.66 0.22 0.83 0.48 1.61 15 AI955897 decrease 1.88 0.64 0.85 0.39 1.00 0.52 1.83 16 X69086 decrease 1.64 0.62 0.65 0.21 0.91 0.44 1.61 17 M80629 decrease 1.72 0.57 0.81 0.40 0.92 0.43 1.61 18 U12022 decrease 1.61 0.48 0.84 0.49 0.80 0.36 1.38 19 X74594 decrease 1.77 0.47 1.02 0.68 0.91 0.48 1.68 20 M64174 decrease 1.76 0.46 1.01 0.68 0.92 0.40 1.56 21 M28212 decrease 1.72 0.43 1.04 0.73 0.87 0.46 1.61 22 U94333 decrease 1.49 0.44 0.79 0.48 0.81 0.47 1.56 23 U13948 decrease 1.41 0.29 0.95 0.74 0.80 0.37 1.38 24 U96919 decrease 1.72 0.86 0.34 −0.28 0.86 0.46 1.61 25 U26398 decrease 1.39 0.47 0.64 0.31 0.70 0.42 1.38 26 AF068836 decrease 1.66 0.53 0.81 0.43 0.88 0.49 1.68 27 L43821 decrease 1.74 0.61 0.77 0.33 1.02 0.49 1.80 28 U17032 decrease 1.63 0.79 0.37 −0.20 0.94 0.61 1.91 29 AB022017 decrease 1.90 0.99 0.32 −0.39 0.74 0.51 1.55 30 AF038897 decrease 1.97 0.75 0.77 0.23 0.80 0.57 1.71 31 HG846-HT846 decrease 1.92 0.88 0.51 −0.12 0.84 0.54 1.70 32 L04288 decrease 2.39 1.48 0.02 −1.05 0.92 0.85 2.28 33 S66213 decrease 2.08 1.14 0.25 −0.57 0.93 0.54 1.79 34 AF052160 decrease 1.86 1.14 0.03 −0.79 0.91 0.65 1.95 35 AB015982 decrease 1.64 0.64 0.62 0.16 0.91 0.58 1.84 36 S79325 decrease 3.05 1.47 0.70 −0.35 0.92 1.13 2.72 37 M55536 decrease 2.89 1.96 −0.25 −1.67 0.88 1.16 2.74 38 X97674 decrease 2.64 1.56 0.15 −0.98 0.91 0.98 2.47 39 U16028 decrease 1.93 1.04 0.26 −0.49 0.85 0.70 1.96 40 M27504 decrease 2.47 1.43 0.18 −0.84 1.01 1.03 2.66 41 U13044 decrease 2.47 1.72 −0.29 −1.53 1.14 0.87 2.53 42 AC004990 decrease 2.57 1.17 0.70 −0.14 0.88 1.06 2.57 43 AF048732 decrease 2.36 1.33 0.23 −0.72 0.97 0.77 2.20 44 AF061261 decrease 1.95 1.14 0.12 −0.70 0.87 0.74 2.06 45 U29671 decrease 2.18 1.19 0.28 −0.58 1.06 0.81 2.36 46 AB023967 decrease 2.07 1.34 −0.07 −1.04 1.11 0.63 2.12 47 U07794 decrease 1.78 0.90 0.34 −0.31 0.94 0.71 2.07 48 U48736 decrease 1.94 1.20 0.02 −0.85 1.01 0.74 2.19 49 AJ001810 decrease 1.70 0.88 0.29 −0.35 0.98 0.72 2.14 50 AI961669 decrease 1.73 0.89 0.31 −0.33 0.93 0.57 1.84 51 Z48579 decrease 1.76 0.92 0.29 −0.38 0.77 0.65 1.81 52 AF047432 decrease 1.82 0.78 0.58 0.01 0.84 0.70 1.95 53 U50553 decrease 1.61 0.63 0.59 0.14 0.92 0.69 2.03 54 U57317 decrease 2.30 1.12 0.51 −0.30 0.97 0.72 2.12 55 U08316 decrease 1.91 0.94 0.40 −0.28 0.89 0.47 1.64 56 X77794 decrease 1.82 0.77 0.60 0.05 1.01 0.58 1.93 57 U43083 decrease 1.94 0.90 0.50 −0.15 0.91 0.53 1.76 58 AF094481 decrease 1.63 0.68 0.54 0.05 0.92 0.41 1.58 59 L12002 decrease 1.70 0.85 0.34 −0.28 0.86 0.44 1.57 60 AB002450 decrease 1.81 1.17 −0.06 −0.90 0.93 0.64 1.96 61 X77723 decrease 1.81 0.72 0.66 0.14 0.93 0.79 2.19 62 M97935 decrease 2.69 1.76 −0.12 −1.39 1.06 0.99 2.65 63 AC002086 decrease 2.08 1.07 0.36 −0.41 0.85 0.58 1.78 64 AF100539 decrease 1.89 0.88 0.48 −0.15 0.90 0.59 1.85 65 AJ001683 decrease 1.86 0.82 0.54 −0.05 1.07 1.01 2.67 66 U13896 decrease 1.71 0.78 0.45 −0.11 0.96 0.87 2.35 67 U57452 decrease 3.12 2.13 −0.29 −1.83 0.95 0.65 1.98 68 X14798 decrease 2.40 1.46 0.07 −0.98 0.92 0.63 1.93 69 D16815 decrease 2.36 1.40 0.11 −0.90 1.01 0.83 2.33 70 L22075 decrease 4.79 4.19 −1.92 −4.94 0.87 1.40 3.10 71 L49229 decrease 3.39 2.63 −0.82 −2.72 1.10 1.78 3.94 72 D13540 decrease 3.60 2.27 −0.02 −1.65 0.99 2.09 4.34 73 W25874 decrease 2.38 1.33 0.25 −0.71 0.70 0.99 2.28 74 AF007111 decrease 2.10 1.22 0.15 −0.73 1.00 0.96 2.54 75 AA013087 decrease 2.94 1.18 1.05 0.20 0.65 0.99 2.24 76 J04101 decrease 3.05 1.70 0.33 −0.90 0.72 1.04 2.38 77 X74837 decrease 1.93 1.09 0.18 −0.61 0.79 0.48 1.56 78 X65873 decrease 1.80 0.63 0.80 0.34 0.79 0.53 1.63 79 U50648 decrease 1.68 0.73 0.51 −0.02 0.86 0.35 1.42 80 X15949 decrease 1.50 0.55 0.63 0.23 0.79 0.39 1.42 81 AI189226 decrease 1.70 0.93 0.20 −0.47 0.85 0.43 1.54 82 D32039 decrease 1.30 0.38 0.69 0.42 0.83 0.58 1.76 83 AL049962 decrease 1.46 0.51 0.63 0.26 0.83 0.47 1.57 84 W27675 decrease 1.34 0.24 0.96 0.79 0.65 0.53 1.49 85 AW006742 decrease 1.50 0.41 0.85 0.55 0.77 0.55 1.64 86 AA457029 decrease 1.36 0.34 0.81 0.56 0.80 0.42 1.47 87 J03069 decrease 1.43 0.47 0.68 0.33 0.86 0.50 1.67 88 Z24459 decrease 1.43 0.30 0.95 0.74 0.87 0.38 1.49 89 AB018340 decrease 1.13 0.17 0.85 0.73 0.72 0.40 1.36 90 X02751 decrease 1.75 0.97 0.19 −0.51 0.81 0.72 1.96 91 U94747 decrease 1.44 0.79 0.17 −0.40 0.72 0.50 1.52 92 AB028971 decrease 1.22 0.24 0.84 0.67 0.72 0.47 1.47 93 AB007923 decrease 1.54 0.56 0.64 0.23 0.82 0.41 1.47 94 AB026891 decrease 1.73 0.99 0.14 −0.58 0.96 0.60 1.92 95 U04735 decrease 1.70 0.63 0.70 0.25 0.95 0.43 1.63 96 X07767 decrease 1.38 0.76 0.16 −0.39 0.83 0.70 1.94 97 AW003733 decrease 1.08 0.36 0.51 0.25 0.84 0.63 1.85 98 AA058762 decrease 1.38 0.73 0.21 −0.31 0.66 0.63 1.67 99 M69177 decrease 3.57 2.74 −0.81 −2.79 1.32 1.83 4.25 100  M20560 increaase 1.97 1.48 4.34 5.41 2.20 2.70 −2.12 101  AB007977 increaase 0.69 0.73 −1.33 −1.00 1.65 1.14 −0.18 102  D10202 increaase 0.58 0.65 −1.37 −0.93 2.09 1.67 −0.58 103  AL048308 increaase 0.66 0.39 −0.39 −0.25 1.24 0.61 0.27 104  X66363 increaase 0.34 0.64 2.14 −1.15 2.32 1.98 −0.84 105  M94345 increaase 0.78 0.28 −0.23 0.13 1.30 0.48 0.53 106  W27466 increaase 0.76 0.24 −0.19 0.20 1.28 0.43 0.60 107  Y15909 increaase 0.68 0.39 −0.37 −0.22 1.27 0.45 0.55 108  X02160 increaase 0.57 0.42 −0.49 −0.40 1.02 0.29 0.56 109  L41827 increase 0.70 0.37 −0.35 −0.16 1.40 0.61 0.42 110  AF026548 increaase 0.54 0.41 −0.49 −0.41 1.28 0.51 0.47 111  X71129 increaase 0.70 0.44 −0.46 −0.33 1.45 0.80 0.18 112  U88153 increaase 0.70 0.41 −0.41 −0.26 1.28 0.65 0.24 113  U08015 increase 0.80 0.24 −0.19 0.25 1.62 0.83 0.29 114  AB011135 increase 0.71 0.34 −0.31 −0.09 1.27 0.58 0.34 115  X13839 increase 0.65 0.41 −0.42 −0.30 1.53 0.81 0.24 116  AF076838 increaase 0.65 0.53 −0.66 −0.57 1.37 0.67 0.31 117  AI762213 increaase 0.81 0.22 −0.16 0.31 1.35 0.86 −0.03 118  AA522537 increaase 0.89 0.42 −0.38 −0.10 1.35 0.94 −0.15 119  U66359 increaase 0.76 0.42 −0.40 −0.21 1.00 0.54 0.13 120  Z80345 increaase 1.08 1.03 −1.60 −1.32 1.06 0.60 0.11 121  L77213 increaase 0.68 0.55 −0.69 −0.59 1.26 0.96 −0.28 122  D17530 increaase 1.05 0.62 −0.62 −0.39 0.89 0.64 −0.13 123  L36645 increaase 0.78 0.46 −0.46 −0.29 1.06 0.55 0.17 124  D64109 increaase 0.60 0.52 −0.71 −0.61 1.41 1.11 −0.36 125  AI039144 increaase 1.11 0.82 −0.95 −0.79 1.40 1.29 −0.67 126  AF000573 increaase 1.27 0.72 −0.70 −0.41 1.33 1.02 −0.30 127  AB016816 increaase 0.66 0.78 −1.90 −1.16 1.54 1.66 −1.12 128  AB023211 increaase 0.72 0.34 −0.30 −0.06 1.29 0.80 0.01 129  AA521060 increaase 0.99 0.31 −0.24 0.28 1.37 0.68 0.28 130  X77094 increaase 0.90 0.41 −0.36 −0.05 1.64 1.11 −0.13 131  HG2689-HT27 increaase 0.72 0.48 −0.51 −0.39 1.32 0.72 0.17 132  AA528252 increaase 1.15 0.48 −0.41 0.02 1.07 0.62 0.08 133  M14648 increaase 1.07 0.42 −0.35 0.09 1.02 0.63 0.01 134  AL049435 increaase 1.07 0.34 −0.26 0.29 1.15 0.64 0.13 135  L40392 increaase 1.13 0.22 −0.16 0.61 1.05 0.64 0.02 136  AB023226 increaase 1.05 0.41 −0.34 0.09 0.96 0.61 −0.01 137  AB018259 increaase 0.84 0.69 −0.90 −0.77 1.03 0.52 0.20 138  AJ132099 increaase 1.22 0.54 −0.47 −0.04 1.08 0.72 −0.07 139  AC004893 increaase 0.88 0.29 −0.23 0.21 1.16 0.70 0.04 140  AB028973 increase 0.73 0.47 −0.49 −0.36 1.15 0.52 0.32 141  AF001549 increaase 1.04 0.58 −0.55 −0.30 1.02 0.78 −0.22 142  X55544 increaase 1.05 0.42 −0.35 0.06 0.89 0.54 0.01 143  AB011120 increaase 0.96 0.40 −0.34 0.04 0.97 0.65 −0.07 144  U01877 increaase 1.28 0.94 −1.08 −0.89 1.36 0.99 −0.23 145  L25851 increaase 1.05 0.40 −0.33 0.12 1.10 0.80 −0.17 146  AI148772 increaase 0.70 0.54 −0.65 −0.55 1.23 1.00 −0.37 147  AL109724 increaase 0.79 0.73 −1.09 −0.91 1.45 1.13 −0.37 148  L12691 decrease 1.64 1.07 −0.08 −0.85 1.84 2.30 5.52 149  AL036554 decrease 1.26 0.82 −0.05 −0.64 1.72 2.30 5.39 150  M34379 decrease 1.71 1.01 0.08 −0.65 2.25 3.42 7.72 151  AF002224 decrease 9.96 11.12 −7.83 −15.84 2.53 6.68 13.22 152  X69089 decrease 5.03 4.83 −2.70 −6.18 1.87 2.35 5.63 253.80 77.84 161.02 54.81 Threshold of patient Total of Welch T test group patient group P Comparison P Comparison 1% Ratio of with acute with chronic No. threshold mean value patient group Significance patient group Significance  1 2.33 0.82 0.049 CN 0.947 NS  2 2.63 0.47 0.027 CN 0.051  3 3.78 0.49 0.404 0.02 CS  4 1.78 0.47 0.043 CN 0.008 CS  5 1.63 0.51 0.044 0.003 CS  6 1.89 0.52 0.082 0.001 CS  7 2.24 0.43 0.184 0.001 CS  8 2.01 0.44 0.056 0 CS  9 1.81 0.55 0.209 0.001 CS 10 1.63 0.52 0.048 0 CS 11 1.59 0.53 0.046 0.001 CS 12 1.72 0.56 0.196 0.001 CS 13 1.79 0.55 0.163 0 CS 14 1.95 0.52 0.247 0.001 CS 15 2.19 0.53 0.255 0.001 CS 16 1.92 0.56 0.276 0.003 CS 17 1.90 0.54 0.215 0.001 CS 18 1.63 0.50 0.041 0 CS 19 2.01 0.51 0.1 0 CS 20 1.84 0.52 0.058 0 CS 21 1.94 0.51 0.137 0 CS 22 1.89 0.55 0.331 0 CS 23 1.64 0.56 0.07 0 CS 24 1.93 0.50 0.198 0.008 CS 25 1.67 0.51 0.037 0.001 CS 26 2.02 0.53 0.093 0.002 CS 27 2.14 0.58 0.421 0.002 CS 28 2.34 0.58 0.497 0.014 CS 29 1.91 0.39 0.029 CN 0.006 CS 30 2.10 0.41 0.083 0.001 CS 31 2.08 0.43 0.152 0.003 CS 32 2.88 0.39 0.117 0.017 CS 33 2.17 0.45 0.134 0.009 CS 34 2.40 0.49 0.222 0.026 CS 35 2.25 0.55 0.418 0.003 CS 36 3.51 0.30 0.232 0.001 CS 37 3.56 0.30 0.274 0.007 CS 38 3.15 0.34 0.238 0.005 CS 39 2.45 0.44 0.3 0.007 CS 40 3.38 0.41 0.425 0.006 CS 41 3.14 0.46 0.478 0.022 CS 42 3.32 0.34 0.276 0.001 CS 43 2.74 0.41 0.22 0.006 CS 44 2.59 0.45 0.384 0.01 CS 45 2.93 0.49 0.438 0.01 CS 46 2.56 0.53 0.354 0.039 CS 47 2.57 0.53 0.49 0.01 CS 48 2.71 0.52 0.57 0.02 CS 49 2.64 0.58 0.943 0.009 CS 50 2.24 0.54 0.514 0.009 CS 51 2.27 0.44 0.259 0.005 CS 52 2.44 0.46 0.298 0.002 CS 53 2.51 0.57 0.554 0.005 CS 54 2.62 0.42 0.144 0.005 CS 55 1.97 0.47 0.12 0.007 CS 56 2.34 0.55 0.348 0.005 CS 57 2.13 0.47 0.193 0.004 CS 58 1.86 0.57 0.243 0.005 CS 59 1.88 0.51 0.195 0.009 CS 60 2.41 0.51 0.316 0.037 CS 61 2.74 0.51 0.593 0.001 CS 62 3.34 0.39 0.321 0.012 CS 63 2.18 0.41 0.139 0.004 CS 64 2.26 0.48 0.092 0.007 CS 65 3.38 0.57 0.756 0.007 CS 66 2.96 0.56 0.61 0.012 CS 67 2.44 0.30 0.041 CN 0.013 CS 68 2.38 0.38 0.11 0.01 CS 69 2.91 0.43 0.274 0.011 CS 70 4.08 0.18 0.1 0.016 CS 71 5.19 0.32 0.44 0.016 CS 72 5.81 0.27 0.399 0.004 CS 73 2.98 0.29 0.146 0.002 CS 74 3.21 0.48 0.424 0.016 CS 75 2.93 0.22 0.115 0 CS 76 3.11 0.24 0.089 0.001 CS 77 1.90 0.41 0.144 0.006 CS NS 78 2.00 0.44 0.054 0 CS 79 1.66 0.51 0.113 0.004 CS 80 1.70 0.53 0.095 0.003 CS 81 1.84 0.50 0.047 0.027 CS 82 2.16 0.64 0.878 0.002 CS NS 83 1.90 0.57 0.346 0.002 CS 84 1.86 0.48 0.131 0 CS 85 2.03 0.51 0.157 0.001 CS 86 1.77 0.59 0.386 0 CS 87 2.02 0.60 0.492 0.002 CS 88 1.76 0.61 0.675 0 CS NS 89 1.63 0.64 0.89 0 CS 90 2.46 0.46 0.186 0.017 CS 91 1.88 0.50 0.084 0.025 CS 92 1.80 0.59 0.025 CN 0.014 93 1.75 0.53 0.027 0.003 CS 94 2.34 0.55 0.4 0.028 CS 95 1.93 0.56 0.164 0.003 CS 96 2.42 0.60 0.908 0.031 CS NS 97 2.29 0.77 0.147 0.037 NS 98 2.12 0.47 0.202 0.017 CS 99 5.53 0.37 0.35 0.025 CS 100  −4.01 1.11 0.037 CN 0.391 NS 101  −0.97 2.39 0.566 0.007 CS 102  −1.74 3.60 0.12 0.011 CS 103  −0.15 1.89 0.362 0.003 CS 104  −2.23 6.86 0.271 0.001 CS NS 105  0.20 1.66 0.035 CN 0.015 106  0.30 1.69 0.003 CN 0.012 107  0.24 1.87 0.022 CN 0.008 108  0.36 1.78 0.002 CN 0.037 109  −0.01 2.00 0.008 CN 0.011 110  0.12 2.36 0.054 0.001 CS 111  −0.38 2.09 0.144 0.008 CS 112  −0.22 1.84 0.211 0.009 CS 113  −0.29 2.02 0.078 0.007 CS 114  −0.07 1.79 0.44 0.002 CS 115  −0.33 2.36 0.239 0.001 CS 116  −0.16 2.10 0.127 0.005 CS 117  −0.63 1.66 0.391 0.006 CS NS 118  −0.81 1.51 0.6 0.052 NS 119  −0.25 1.30 0.18 0.06 NS 120  −0.31 0.98 0.121 0.575 NS 121  −0.96 1.86 0.016 CN 0.168 122  −0.58 0.85 0.015 CN 0.848 NS 123  −0.21 1.36 0.473 0.043 NS 124  −1.14 2.35 0.771 0.01 CS NS 125  −1.57 1.26 0.188 0.241 NS 126  −1.02 1.05 0.046 0.426 NS 127  −2.29 2.34 0.205 0.019 CS NS 128  −0.55 1.79 0.044 CN 0.149 129  −0.19 1.38 0.005 CN 0.565 130  −0.91 1.83 0.035 CN 0.179 131  −0.33 1.84 0.005 CN 0.135 132  −0.36 0.93 0.013 0.161 NS 133  −0.42 0.95 0.08 0.064 NS 134  −0.32 1.07 0.036 0.119 NS 135  −0.43 0.93 0.08 0.008 NS 136  −0.43 0.92 0.044 0.106 NS 137  −0.17 1.23 0.012 0.791 NS 138  −0.57 0.88 0.016 0.027 NS 139  −0.45 1.31 0.034 CN 0.977 NS 140  −0.05 1.57 0.013 CN 0.225 141  −0.77 0.98 0.135 0.294 NS 142  −0.37 0.85 0.11 0.082 NS 143  −0.52 1.01 0.005 0.117 NS 144  −0.93 1.06 0.095 0.492 NS 145  −0.73 1.05 0.001 0.477 NS 146  −1.08 1.75 0.006 CN 0.891 NS 147  −1.16 1.84 0.003 CN 0.316 148  7.13 1.12 0.007 CN 0.325 NS 149  7.00 1.36 0.016 0.202 NS 150  10.12 1.32 0.007 CN 0.278 151  17.90 0.25 0.613 0.04 CS 152  7.27 0.37 0.578 0.041 CS

It was determined that the genes listed in Table 1 are particularly useful as an index for diagnosis of schizophrenia, in consideration of all of the following criteria on a DNA chip:

-   (1) having reliable signal intensity, -   (2) exhibiting gene-expression alteration ratio of more than     two-folds or less than half, wherein the gene-expression alteration     ratio is determined by either one of “comparison of the average     expression levels between the non-treated acute patient group and     the healthy subject group” or “comparison of the average expression     levels between the chronic patient group in hospital and the healthy     subject group”, (3) exhibiting p-value of 0.05 or less obtained from     test of difference in the average level of gene expression between     the patient group and the normal group. Note that the term “p-value”     is the probability of measuring a certain statistical value     according to null hypothesis. Therefore Table 1 consists of sum of     the list of genes obtained by two kinds of statistic comparison as     follows: (1) comparison of the average expression levels of genes     between the non-treated acute patient group and the healthy subject     group, and (2) comparison of the average expression levels of genes     between the chronic patient group in hospital and the healthy     subject group. Therefore, when the patient group was defined as the     sum of the non-treated acute patient group and the chronic patient     group in hospital, comparison between the average expression levels     of genes in the patient group and that in the healthy subject group     does not necessarily result in the p value (significance in     probability) of less than 0.05.

It was shown that the genes listed in Table 2 can satidfiy all of the following criteria on a DNA chip:

-   (1) having reliable signal intensity, -   (2) exhibiting gene-expression alteration ratio of more than     two-folds or less than half, wherein the gene-expression alteration     ratio is determined by “comparison of the average expression levels     between the non-treated acute patient group the chronic patient     group in hospital”, -   (3) exhibiting p-value of 0.05 or less obtained from test of     difference in the average level of gene expression, when the     non-treated acute patient group was compared with the chronic     patient group in hospital. The genes exhibit alteration with     progression of schizophrenia, and thus assumed to reflect the     pathology of schizophrenia itself. Therefore, when only the average     expression levels of genes were compared between the patient group     and the healthy subjects, the comparison does not necessarily result     in the p value of less than 0.05.

However, for the purpose to improve accuracy of diagnosis and to discriminate the acute phase and chronic phase of schizophrenia (in details, refer to the following Example) the “gene(s) exhibiting altered expression by progression of schizophrenia” can be selected for the purpose of this diagnosis, then the accuracy of diagnosis can be increased. The genes and proteins to be used as the index may be selected from these genes or proteins, in the simplest may be selected based upon the p value alone or the gene-expression alteration ratio alone, otherwise may be selected based upon the standard deviation of the normal group, theta of non-treated acute patient group or that of chronic patients group in hospital.

When the index gene is selected on the basis of p value alone as the criteria, the index gene may preferably have the p value of 0.2 or less, 0.15 or less, more preferably 0.10 or less and more 0.05 or less. Further preferably, the index gene may have the p value of 0.02 or less, 0.01 or less, 0.005 or less, 0.025 or less, 0.002 or less, 0.001 or less.

When the index gene is selected on the basis of the gene-expression alteration ratio alone as the criteria, the index gene may have the gene-expression alteration ratio of 2.0 or more, preferably the gene-expression alteration ratio of 2.1 or more, 2.2 or more, 2.25 or more, 2.5 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 7.5 or more, 8 or more, 9 or more, 10 or more.

Moreover, the method of the present invention can be utilized for the purpose to diagnose objectively whether a test subject suffers from schizophrenia or not, using the expression of the gene or fragment thereof and/or the protein encoded by the gene or fragment thereof satisfying the aforementioned criteria.

According to this specification, the term “schizophrenia” includes any type of schizophrenia such as paranoid schizophrenia, disorganized schizophrenia, catatonic schizophrenia, and a type of schizophrenia incapable to be classified. As to genes involved in schizophrenia, genetic polymorphism of these genes has been known. Therefore, by using a DNA chip, a method capable of capturing expression of larger number of gene is identical, then a method to diagnose “schizophrenia” based upon plural criteria on gene expression is developed as described in this specification. Thus among genes listed in Table 1 and Table 2 described above, gene expression may measured on one gene, preferably 2 genes, more preferably 5 genes, 10 genes, 20 genes, 30 genes, 50 genes, 100 genes, and determination may be performed comprehensively.

According to the method of the present invention, at least one nucleic acid or its fragment and/or at least one protein or its fragment encoded by the nucleic acid selected from the group consisting of the genes represented by the Genbank accession no. described in Table 1 and Table 2 may be quantified. In some cases, plural protein names or plural Genbank accession nos. may be registered or become to be popular for one gene, a nucleic acid specified as such is also included within the scope of this invention.

The “nucleic acid(s) complementary to the nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia” typically means mRNAs and cDNAs of genes represented by the Genbank accession no. described in Table 1. Moreover, the “nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia” typically means mRNAs and cDNAs of genes represented by the Genbank accession no. described in Table 2. Furthermore, any polynucleotides, such as regulatory sequences or polyadenyl sequences, may be included in the terminal ends of the translation region and/or inside of these mRNA or cDNA.

The “fragment of a nucleic acid defining gene(s) exhibiting altered expression by occurrence of schizophrenia” means a polynucleotide consisting of a part of nucleic acid(s) defining gene(s) represented by the Genbank accession no. described in Table 1 while retaining its biological function. Typically, it may be a restriction fragment of a mRNA or a cDNA corresponding to the gene represented by the Genbank accession no. described in Table 1. In the same manner, the “fragment of a protein encoded by a nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia” means a polypeptide consisting of a part of protein(s) encoded by the nucleic acid(s) defining gene represented by the Genbank accession no. described in Table 1 while retaining its biological function.

Moreover, the “fragment of a nucleic acid defining gene(s) exhibiting altered expression by progression of schizophrenia” means a polynucleotide consisting of a part of nucleic acid(s) defining gene(s) represented by the Genbank accession no. described in Table 2 while retaining its biological function. Typically, it may be a restriction fragment of a mRNA or a cDNA corresponding to the gene represented by the Genbank accession no. described in Table 2. In the same manner, the “fragment of a protein encoded by a nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia” means a polypeptide consisting of a part of protein(s) encoded by the nucleic acid(s) defining gene represented by the Genbank accession no. described in Table 2 while retaining its biological function.

The term “nucleic acid” used in this specification may include any polynucleotide consisting of simple nucleotides and/or modified nucleotides such as cDNA, mRNA, total RNA and hnRNA. The term “modified nucleotides” may include phosphoric esters such as inosine, acetylcytidine, methylcytidine, methyladenosine and methyl guanosine, as well as other postnatal nucleotides which may be produced by the effect of ultraviolet rays or chemical substances.

Mononuclear cell in blood is also called monocyte, which is a cell having single nuclear in blood and corresponds to large lymphocyte. Macrophage in inflammatory sites is included herein and such vell exhibits strong phagocytic effect. Erythrocyte may removed from total blood cell fraction treated by anti-coagulant under non-isotonic condition, and blood cell fraction thus obtained may be purified by classification according to cell volume using sucrose density-gradient centrifugation method or ficoll centrifugation method.

In general, to achieve quantification of nucleic acids, a sample may be obtained from a test subject, which is succeeded by extraction of ribonucleic acid from the sample. Extraction of the nucleic acid from a component of living body may be achieved by any extraction method such as phenol extraction and ethanol precipitation. To achieve extraction of mRNA, the sample may be passed through an oligo-dT column.

In the case where the amount of the nucleic acid is not large, the nucleic acid may be amplified, if necessary. The nucleic acid may be amplified by polymerase chain reaction (hereinafter, simply referred to as “PCR”), for example, by reverse transcriptase PCR (RT-PCR). Furthermore, as described in the following description, the amplification may be performed as a quantitative operation or the quantitative operation may be combined with other operations.

After the extraction procedure and/or the amplification procedure (if necessary) may be achieved, at least one nucleic acid or fragment thereof selected from the group consisting of nucleic acids defining genes represented by GenBank Accession nos. listed in Table 1 or 2, may be quantified. Otherwise, at least one protein or fragment thereof encoded by the nucleic acid may be quantified.

The nucleic acid may be quantified by any conventional known method, such as quantitative PCR, Northern blotting, RNase protection mapping, or a combination of such methods. In the case the kinds of genes to be quantified is small, these methods of quantitative PCR, Northern blotting, RNase protection mapping may be effective. In the Example, a DNA chip is utilized, however, above-mentioned procedures are simpler and lower in price. However, the embodiment of the present invention is not limited to that utilizing a DNA chip.

The internal nucleotides of the amplified products may be labeled in the quantitative PCR, typically by using radio-labeled nucleotides (e.g., ³²P). Alternatively, the amplified product may be endo-labeled by using radio-labeled primers. Free radio-labeled nucleotides or radio-labeled primers may be separated from the labeled amplified products, by using some known methods including gel filtration, alcohol precipitation, trichloroacetic acid precipitation and physical absorption using a glass filter. Thereafter, procedures such as electrophoresis and hybridization may be performed (or may not be performed) and the amplified products may be quantified by using liquid scintillation, autoradiography, and imaging plate Bio-Imaging Analyzer (BAS; Fuji Photo Film Co., Ltd.). Instead of such radioactive substance, a fluorescent substance or a luminescent substance may be used as a labeling substance, and the amplified product may be quantified by means of spectrofluorometer, fluoromicro plate reader or CCD camera. Furthermore, in the case where incorporation of the labeling substance into the amplified product is not performed during the PCR operation, an intercalate fluorescent pigment such as ethidium bromide, SYBR Green I™, PicoGreen™ (manufactured and sold by Molecular Probes) may be used to detect the amplified product.

In the case where the quantitative PCR may not be performed, the sample containing nucleic acid may be subjected to electrophoresis, and then analyzed by Southern blotting or Northern blotting, thereafter quantification may be achieved by using a probe labeled with a detectable marker.

In the case where many kinds of nucleic acids are to be quantified simultaneously, DNA chip or DNA microarray may be used together with or instead of the aforementioned techniques. In this case, many kinds of nucleic acids can be quantified and analyzed at one procedure, such means is useful for multiplication of probabilities and for linear discriminant analysis. Moreover, a DNA chip or a DNA micro-array on which the “nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia” is immobilized may be prepared for the purpose to be applied in diagnosis of schizophrenia and a kit may be also prepared. Various methods can be adopted to prepare a DNA or a DNA micro-array on which a nucleic acid is immobilized, such methods are well known to those skilled in the art. In concrete, DNA may be arranged onto a substrate at extremely high density and the arranged DNA may be analyzed, otherwise, DNA may be synthesized directly on a substrate. Arrangement of DNA on a substrate at extremely high density may be achieved by utilizing a commercially available spotter.

Instead of quantification of the nucleic acid or together with quantification of the nucleic acid, the amount of gene expression may be indirectly determined by quantifying the amount of protein produced from the nucleic acid (gene). When schizophrenia is diagnosed according to the method of the present invention, in many cases, the indirect method of quantifying protein(s) encoded by nucleic acid(s) may be more useful than the direct method of quantifying nucleic acid(s). Therefore, in the case a nucleic acid is to be quantified indirectly by quantification of a protein, it is preferred to investigate on the extent of the alteration of the protein to be quantified observed in a schizophrenic patient in comparison with healthy subjects (non-mental patient).

For the method of protein extraction from cells and for the method of protein quantification, any methods known in this field may be used. The proteins (gene products) produced in many blood cells are released into blood in many cases, therefore, proteins in blood, plasma or serum can be used as a sample of a test subject. Examples of methods for protein quantification may include Western blotting method and enzyme-linked immunosorbent assay method including solid-phase enzyme-linked immunosorbent assay, immunocytochemistry, and immunohistochemistry. Alternatively, in the case an antibody toward the target protein is available, cells may be labeled by fluorescence by means of immunocytochemistry and the fluorescent intensity of the cells may be quantified by cell sorter, thereby determination may be achieved.

Meanwhile, only summary of the conventional procedures are schematically exemplified in this specification, however, such description should not be interpret to limit the range of this invention. Therefore, modified or alternative methods of the aforementioned methods can be also utilized.

Extraction, amplification, isolation, and quantification of the nucleic acid can be performed automatically by using an automatic operation device currently on the market, in which an electrophoresis device and a PCR device and the like are combined, therefore, utilization of such device may be preferred. By using such an automatic machine, diagnosis of schizophrenia can be achieved in the same manner as routine clinical tests.

After quantification of a prescribed nucleic acid, whether a test subject suffers from schizophrenia or not may be determined, using the quantified value as the index. In the case diagnosis is made by using quantitative value of a singular nucleic acid as the index, the threshold value may be determined appropriately with reference to a normal value. Then, if the quantified value is higher or lower than the threshold value, it is highly possible that the test subject suffers from schizophrenia. In the group of genes listed in Table 1, the genes described in No.1 to No.98 and No.129 to No.132 exhibit decreased expression by occurrence of schizophrenia. Therefore, if the quantified value is lower than the predetermined threshold of healthy subjects, the test subject can be diagnosed to be schizophrenic at high probability.

Meanwhile, in the group of genes listed in Table 1, the genes described in No.99 to No.128 exhibit increased expression by occurrence of schizophrenia. Therefore, if the quantified value is higher than the predetermined threshold of healthy subjects, the test subject can be diagnosed to be schizophrenic at high probability. Moreover, in the group of genes shown in Table 3, 24 genes attached with “CN” mark are included in a gene group obtained by the comparison between the healthy subjects and non-treated patients, whereas 111 genes attached with “CS” mark are included in a gene group obtained by comparison between healthy subjects and chronic patients

Conversely, as to genes described in No.1 to No.98 and No.129 to No.132 of Table 1, when the quantified values of these nucleic acids obtained from a test subject are higher than the known threshold of overall schizophrenic group, the test subject is not included in the patient group. That is, the test subject is diagnosed to be “normal”. In the same manner, as to genes described in No.99 to No.128 of Table 1, when the quantified values of these nucleic acids obtained from a test subject are lower than the known threshold of acute and chronic schizophrenic groups, the test subject is not included in the patient group. That is, the test subject is diagnosed to be “normal”.

At present, schizophrenia is considered to be a syndrome consisting of plural diseases (paranoid type schizophrenia, disorganized type, catatonic type schizophrenia and a type of schizophrenia incapable to be classified). Therefore, it is desired to diagnose in comprehensive manner by combination of plural genes applicable for determination of schizophrenia at high probability, rather than diagnosis based upon only singular gene.

The threshold value may be selected depending upon the accurately of the diagnosis required, as shown below.

When distribution on the amount of gene expression is elucidated on both the non-schizophrenic group (hereinafter, referred to as normal group) and the schizophrenic group (hereinafter, simply referred to as patient group) groups, the upper threshold or the lower threshold may be selected in such a manner that an individual (from which the nucleic acids to be determined have been obtained) belongs to the normal group with probability of 10%, 5%, or 1%.

When distribution on the amount of gene-expression is elucidated for only the normal group, it can be hypothesized that an individual (from which the nucleic acids to be determined have been obtained) belongs to the normal group. Under this hypothesis, the threshold (the amount or concentration of nucleic acid) may be determined so as to such quantified value can be obtained with a probability (hereinafter, referred to as p-value, one-sided probability may be also utilized for the direction of the alteration is known in advance) of 10%, preferably 5%, more preferably 1%. For example, null hypothesis can be verified using the value of the gene expression level obtained from a DNA chip, in accordance with the 5% threshold value or the 1% threshold value represented in Table 3, that is; the sample having the determined value is included in the normal group or patient group.

In a method for determination of nucleic acid not using a DNA chip, when a part of genes or plural genes described in Table 1 and Table 2 are adopted to determine whether a subject is “normal” or “abnormal”, the distribution and variance of the gene may preferably be investigated on healthy subjects and schizophrenic patients in advance. In that case, when distribution of the gene expression has been elucidated only one of the healthy subject group and the patient group, analysis can be made using identical statistical method. The p-value can be calculated by a statistical method such as t-test or non-parametric test.

To elucidate statistical distribution of gene-expression on the normal group and/or the patient group, it is generally required that at least 5 individuals, preferably 10 individuals, more preferably 20 individuals, more preferably 30 individuals, further preferably 50 individuals and the most preferably 100 individuals are to be measured.

Moreover, depending on the correlation with schizophrenia or reliability of the determination, the plural genes selected may be treated by addition at different weights, and the multiplication or mathematical conversion may be performed on the values of expression levels of individual genes to increase the accuracy of determination. It is also possible to determine whether a test subject suffers from schizophrenia or not with higher accurately by using arbitrary statistic methods of various kinds, thus a diagnostic method using such statistic methods should be included within the scope of the present invention.

In the case where diagnosis is made using the quantified value of a singular nucleic acid as the index, as described in detail in the following Examples, the singular nucleic acid may preferably satisfy following criteria; (1) the amount of expression in either of the normal group or the patient group is high (2) the absolute gene-expression alteration ratio between the normal group and patient group is 2.0 or more (refer to “Examples”), and (3) the p-value in the test of mean-values difference is 5% or less.

In the case where diagnosis is made using the quantified values of plural nucleic acids, appropriate thresholds should be determined on each of the nucleic acids. Then diagnosis can be made in the same manner when a singular nucleic acid is used as the index, by examining whether the amount of gene expression is higher or lower than the threshold for individual genes.

If one quantified value of the nucleic acid(s) is higher or lower than the threshold in accordance with the accuracy required, the test subject may be diagnosed to be schizophrenic. If more than two quantified values of the nucleic acid(s) are higher or lower than the thresholds, the test subject may be diagnosed to be schizophrenic at higher possibility. In the case confirmed diagnosis is required, when more numbers of the quantified values of nucleic acids are above or below compared with the threshold, the diagnosis of schizophrenia can be made with more accurately. It is also possible to make determination using the amount of expression of these plural genes through statistic calculation such as mathematical formula, multiplication of probabilities and weighted linear addition.

The diagnostic method of the present invention can be used together with the conventional subjective diagnostic method. Moreover, if quantified data on the amount of nucleic acid(s) can be collected from patients clearly suffering from schizophrenia (determined by some means) and such data is applicable as the index for the diagnostic method of the present invention, it is possible to make confirmed diagnosis by the method of the present invention alone.

The subject of the present invention is to provide a method for objective diagnosis for schizophrenia, therefore, not to provide particular individual procedures for extraction, amplification and analysis described concretely in this specification. Hence, it should be noted that diagnostic method utilizing other than above-mentioned procedures are also include in the scope of present invention.

As described in the above, according to the method of the present invention, objective diagnosis can be made on whether a test subject suffers from schizophrenia or not, by using the amount of expression of nucleic acid (gene) as an index.

Moreover, the method of this invention is also useful for diagnosis of transition of schizophrenia; i.e. from acute phase to chronic phase of schizophrenia. In concrete, the genes described in Table 2 are included in a group of genes exhibiting difference in the expression between the acute patient group and the chronic patient group, therefore, these genes reflect pathologic alteration of schizophrenia. Therefore, using the genes listed in Table 2 as an index, objective diagnosis can be made on whether the pathology of a test subject is at the acute phase of schizophrenia or the pathology of test subject is changing to the chronic schizophrenia.

The diagnostic method of the present invention can be applied to a psychiatric assessment for the purpose to examine whether a subject is legally responsible or not, and to a psychiatric assessment performed for other purposes.

Furthermore, the method of this invention can be utilized in development of a medicine for treatment of schizophrenia. In such case, a candidate compound to be screened may be administrated to a model animal of schizophrenia. If the model animal recovers from schizophrenia, it may be determined that said candidate substance is effective as an anti-schizophrenic agent. In concrete, for example, when the quantified level of the nucleic acid(s) defining gene(s) exhibiting decreased expression by schizophrenia (Table 1, No.1-98 and No.129-132) approaches to the control level with significance compared with the level of the nucleic acid(s) measured prior to administration of said candidate compound, said candidate compound may be effective as an anti-schizophrenic agent. For example, if the level of the nucleic acid(s) defining gene(s) exhibiting altered expression with significance in non-treated acute patients described in Table 3 or gene products thereof is quantified and the quantified level approaches to the normal level with respect to a chronic patient in hospital who received treatment a medicine, such alteration the quantified value(s) of the gene(s) is assumed to reflect the effect of the medicine. In concrete, No.1 (Homo sapiens cDNA, 3 end/clone=IMAGE-2329930 EST wd33c06.x1: Genbank No. AI677689), No.100 (lipocortin-III: Genbank No. M20560), No.146 (Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1: Genbank No. AI1487729), No.139 (Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1: Genbank No. AC004893) and defensin alpha 3: Genbank No. L12691) are included within such gene.

Furthermore in the genes listed in Table 1 or Table 2, determination of the expression levels of genes (the amount of mRNA) involved in protein phosphorylation or de-phosphorylation is particularly useful in diagnosis of schizophrenia. In concrete, by linear discriminant analysis on the expression levels of the genes encoding following 16 kinds of proteins, it is possible to discriminate schizophrenic patients from healthy subjects; (1) Ndr protein kinase (Genbank No.Z35102), (2) protein-tyrosine kinase JAK1 (Genbank No.M64174), (3) inositol polyphosphate 4-phosphatase type I-beta (Genbank No.U96919), (4) AMP-activated protein kinase alpha-1 (Genbank No.AB022017), (5) Protein C kinase Nu (EPK2) : EPK2 mRNA for serine/threonine kinase (Genbank No.AB015982), (6) MEK kinase (Mekk) (Genbank No.U29671), (7) HSTXK Human tyrosine kinase (TXK) (Genbank No.U07794), (8) serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No.U48736), (9) ribosome protein S6 kinase, insulin-stimulated protein kinase 1 (ISPK-1) (Genbank No.U08316), (10) Human SNF1-like protein kinase (Genbank No.U57452), (11) SH-PTP3 for protein-tyrosine phosphatase (Genbank No.D13540), (12) interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No.U50648), (13) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No.X07767), (14) PCTAIRE-1 for serine/threonine protein kinase (Genbank No.X66363), (15) branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No.AF026548) and (16) Phosphomevalonate kinase (Genbank No.L77213).

The levels of these genes are not altered in depressive patients and in panic disorders compared with control, then the diagnostic method according to this method is effective to discriminate schizophrenia from these other psychiatric diseases. Moreover, in the embodiment where plural genes are combined in the diagnosis, above-mentioned 16 genes may preferably be included within the target genes to be measured for the purpose to achieve higher accuracy.

Now, the present invention will be further explained in detail with reference to Experimental Examples, which will not limits the scope of the present invention in any sense.

EXAMPLES

In this Embodiment, explanation will be provided on the genes identified by the present inventors and available as a marker for diagnosis of schizophrenia.

In this study, blood sample was obtained from (1) acute schizophrenic patients (non-treated, samples N1 to N5), (2) chronic schizophrenia patients in hospital (treated by medicine, samples S1 to S12), and (3) normal volunteers without psychiatric disease (samples C1 to C9), in the presence of anticoagulant using a Venoject vacuum blood collection tube. Then mononuclear cells were separated and purified from the blood and RNA was extracted using an Isogen nucleic acid extraction kit (Nippon Gene).

According to the protocol provided by Affynmetrix Co., cDNA was synthesized by transcriptase using an oligo dT primer with T7 promoter, and double strand DNA was prepared using E.coli DNA polymerase. The DNA was purified, and cRNA was transcribed by T7 RNA synthase using a biotin UTP as a substrate. The obtained cRNA was fragmented by the treatment with a solution containing magnesium acetate and potassium acetate. A 30 μg of the cRNA was hybridized with Genechip-U95A (version 2, Affymetrix), then expression of the gene was measured all together and patterning (molecular expression profiling) was performed. The hybridization signal was visualized by fluorescence using avidin/R-Phycoerythrin. The signal was read with a fluorescent reader (Gene array scanner G2500A, Hewlett-Packard). Signals from gene spots were analyzed using a Microarray Suite program (Affymetrix). The signal intensities were determined from the sum of the signals from perfect matches (PM) oligo probes, by subtracting the sum of signals from miss match (MM) oligo probes. To compensate for the variation among different DNA chips, the result was calibrated by representing the values as the ratios toward the median of the positive genes on each of the DNA chips to give normalized signal intensities.

To confirm genes exhibiting widespread alteration in plural schizophrenic patients, two comparisons were performed separately, i.e. the comparison between the acute schizophrenic group (samples N1 to N5) and the normal volunteer group (samples C1 to C9), the comparison between the chronic schizophrenic group (samples S1 to S12) and the normal volunteer group (samples C1 to C9). Table 4 shows the data obtained from the normal volunteers C1-C9. Table 4-1 shows the results from the individual subjects, and Table 4-2 shows averages and standard deviations (S.D.) obtained from the data. Table 5 shows the data from non-treated patients N1-N5 and data from treated chronic patients S1-S12. Table 5-1 shows the values on the non-treated patients, Table 5-2 shows the values on the treated patients respectively, and Table 5-3 shows averages and standard deviations obtained from the data. TABLE 4-1 Healthy Healthy Healthy Healthy Healthy Healthy Healthy Healthy Healthy Individual subject subject subject subject subject subject subject subject subject Genbank Gene No. C1 C2 C3 C4 C5 C6 C7 C8 C9 U26398 25 1.01 1.25 1.27 0.99 2.33 1.83 1.61 1.40 0.85 J04101 76 0.37 4.55 1.09 4.95 3.33 5.32 2.83 2.96 2.05 AW006742 85 1.71 1.36 1.01 1.73 1.82 1.57 2.02 0.73 1.59 AB028971 92 1.05 1.60 0.99 1.23 1.26 1.49 1.33 0.83 1.24 AW003733 97 1.36 0.82 1.65 1.02 0.45 1.44 1.05 0.97 0.97 D10202 102 0.50 10.00 1.12 6.54 3.10 2.88 10.00 0.90 2.53 L41827 109 1.05 1.61 1.14 7.85 0.75 2.85 1.08 2.65 1.37 U08015 113 1.21 1.32 1.53 0.85 3.18 1.01 1.03 1.33 1.24 AB028973 140 0.90 2.74 2.67 1.53 6.77 1.79 1.10 1.33 0.59 AL036554 149 0.36 1.54 0.00 1.46 2.65 1.00 0.77 1.60 1.99 AF002224 151 1.29 1.90 12.03 4.89 26.43 27.89 15.20 0.00 0.00 −7.00 4.00 3.00 3 7.00 7.00 −1.00 −3.00 0.00

TABLE 4-2 Standard Genbank Mean Deviation U26398 1.39 0.47 J04101 3.05 1.70 AW006742 1.50 0.41 AB028971 1.22 0.24 AW003733 1.08 0.36 D10202 1.73 1.53 L41827 1.43 2.69 U08015 1.24 4.15 AB028973 1.37 2.13 AL036554 1.26 0.82 AF002224 9.96 11.12

TABLE 5-1 Non-treated Non-treated Non-treated Non-treated Non-treated Individual patient patient patient patient patient Genbank Gene No. N1 N2 N3 N4 N5 U26398 25 0.67 1.31 1.05 0.93 0.73 J04101 76 1.57 3.16 0.00 2.45 0.12 AW006742 85 1.76 1.52 0.71 0.34 0.79 AB028971 92 1.01 0.00 0.79 0.83 0.14 AW003733 97 1.59 1.60 1.37 0.83 1.50 D10202 102 0.40 3.71 0.35 0.44 2.31 L41827 109 0.62 1.21 0.53 0.62 0.74 U08015 113 0.56 1.49 0.44 0.61 1.00 AB028973 140 0.92 0.90 0.60 0.64 0.46 AL036554 149 0.00 0.57 0.00 1.00 0.00 AF002224 151 5.52 27.27 0.00 0.00 0.00 −7.00 1 −9.00 −11.00 −9.00

TABLE 5-2 Chronic Chronic Chronic Chronic Chronic Chronic Chronic Chronic Chronic Chronic Chronic Chronic treated treated treated treated treated treated treated treated treated treated treated treated Individual patient patient patient patient patient patient patient patient patient patient patient patient Genbank Gene No. S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 U26398 25 0.42 0.80 1.20 0.00 1.06 0.46 0.00 0.00 1.08 0.51 0.71 1.05 J04101 76 0.00 0.00 0.24 0.00 0.00 0.91 0.00 0.00 2.30 1.15 0.00 0.36 AW006742 85 1.09 0.57 1.65 0.29 0.99 0.14 0.21 0.90 0.36 0.15 0.31 1.35 AB028971 92 0.32 0.71 0.62 0.57 0.18 1.37 1.10 1.06 0.81 1.12 1.57 0.00 AW003733 97 0.08 0.98 1.06 0.78 0.06 0.00 0.00 0.19 0.15 1.09 1.70 1.24 D10202 102 0.32 0.26 0.47 4.80 0.28 0.76 0.39 0.16 0.39 1.61 10.00 1.25 L41827 109 0.66 0.61 0.36 1.14 0.95 1.16 0.58 0.59 0.45 2.45 0.84 2.00 U08015 113 0.67 0.27 0.36 0.49 1.22 1.00 1.12 0.91 0.91 1.10 0.55 0.38 AB028973 140 2.89 0.70 0.61 0.74 0.83 2.02 1.23 1.22 1.67 0.71 0.66 3.19 AL036554 149 3.80 0.00 3.74 1.33 7.19 0.00 6.82 0.72 0.85 1.36 1.14 0.71 AF002224 151 1.37 0.00 2.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.46 −9.00 −11.00 −9.00 −9.00 −9.00 −7.00 −9.00 −11.00 −9.00 −3.00 −5.00 −5.00

TABLE 5-3 Standard Ratio of Genbank Mean deviation Mean value U26398 0.70 0.42 0.51 J04101 0.72 1.04 0.24 AW006742 0.77 0.55 0.51 AB028971 0.72 0.47 0.59 AW003733 0.84 0.63 0.77 D10202 0.48 0.60 0.28 L41827 0.72 1.63 0.50 U08015 0.62 1.20 0.50 AB028973 0.87 1.92 0.64 AL036554 1.72 2.30 1.36 AF002224 2.53 6.68 0.25

In this Example, the genes described in Table 1 were obtained by screening 12,000 genes that satisfy following three criteria:

-   (1) having reliable signal intensity by PRESENCE Call on DNA chip, -   (2) exhibiting gene-expression alteration ratio of more than     two-folds or less than half, wherein the gene-expression alteration     ratio is determined by either one of “comparison between the average     expression level of the non-treated acute patient group and the     average expression level of the healthy subjects”, “comparison     between average expression level of the chronic patient group in     hospital and the average expression level of the healthy subjects”,     or “comparison between the average expression level of the     non-treated acute patient group and the average expression level of     the chronic patient group in hospital”, and -   (3) exhibiting p-value of 0.05 or less when the difference on the     average gene expression level is examined by Welch's t-test for     significant difference on the following groups; the difference     between the patient group (either one of the non-treated group (CN)     or treated chronic group (CS)) and the normal group, or the     difference between the non-treated acute patient group and the     treated chronic group (NS). Twenty-four genes were identified by     comparing the average expression levels between the non-treated     acute patient group and the normal group; 111 genes were identified     by comparing the average expression levels between the treated     chronic patient group and the normal group; and 34 genes were     identified by comparing the average expression levels between the     non-treated acute patient group and the treated chronic patient     group. These genes exhibited significant alteration by acute or     chronic schizophrenia.

Accordingly, these genes described in Tables 1 and 2 selected according to the above criteria are particularly useful as an index for diagnosis of schizophrenia. The data on the averages, distributions and probabilities (described in Table 3) obtained from the DNA chips of the following Examples are useful for creating criteria for practical diagnosis of schizophrenia.

Example 1 Singular Determination

In this Example, description will be given about a diagnostic method for schizophrenia based upon one gene, using peripheral blood from a patient and adopting the expression level of mRNA for erythroblastosis virus oncogene homolog 1 (ETS-1) protein (v-ets avian erythroblastosis virus E26 oncogene homolog 1, Genbank Accession No.J04101) as a criteria.

First, mononuclear cells were isolated from the peripheral blood of the patient, and pure RNA was extracted by acid-phenol extraction. The RNA was treated according to the protocol provided by Affimetrix, and cDNA, dDNA and cRNA were prepared, then they were fragmented and hybridized with a DNA chip (U34Human). The amount of mRNA for ETS-1 protein (GenBank Accession No.J04101) was determined, and the result was represented by the ratio relative to the median obtained from all genes that gave significant signals on the DNA chip for normalization of the results.

From the data listed in Tables 4 and 5, the distributions on the control group and the patient group are as follows;

-   (1) Distribution of control group (N=9): Average 3.05; Standard     deviation 1.70; 5% lower limit threshold, 0.33 -   (2) Distribution of patient groups (N=17): Average 0.72; Standard     deviation 1.04; 5% upper limit threshold 2.38; 1% upper limit     threshold 3.13

As seen from Tables 3 and 4, the values of the total 26 samples actually used for the study were; (C1) 0.37, (C2) 4.55, (C3) 1.09, (C4) 4.95, (C5) 3.33, (C6) 5.32, (C7) 2.83, (C8) 2.96, (C9) 2.05, (N1) 1.57, (N2) 3.16, (N3) 0.00, (N4) 2.45, (N5) 0.12, (S1) 0.00, (S2) 0.00, (S3) 0.24, (S4) 0.00, (S5) 0.00, (S6) 0.91, (S7) 0.00, (S8) 0.00, (S9) 2.30, (S1O)1.15, (S11) 0.00, and (S12) 0.36. The values from four subjects (C2, C4, C5 and C6) were higher than the 1% upper limit threshold of the distribution of the patient group (3.13), and they were determined to be not included in the schizophrenic group at 99% reliability. That is, they were judged to be “normal.”

In contrast, the expression levels of the gene obtained from ten patients (N3, N5, S1, S2, S3, S4, S5, S7, S8 and S11) were lower than the 5% lower limit threshold of the distribution of the control group (0.33). Therefore, they were determined to be not included in the non-schizophrenic (normal) group at 95% reliability. That is, they were determined to be “abnormal.” As to the remaining 12 subjects, diagnosis could not be made on them. Therefore, as long as the above criteria were used, false diagnosis such as taking a subject included in the control group as “abnormal” or taking a subject included in the patient groups as “normal” could be avoided.

Example 2 Combined Determination

In this Example, description will be given on diagnostic method with higher accuracy. In this method, mononuclear cells from peripheral blood of a patient were used, and the expression level of one gene was determined; i.e. mRNA for erythroblastosis virus oncogene homolog 1 (ETS-1) protein (v-ets avian erythroblastosis virus E26 oncogene homolog 1, GenBank Accession No.J04101), and the expression level was combined with the expression levels of two genes; i.e. gene for KIAA1048 protein (GenBank Accession No.AB028971) and gene for NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2497327 3′ similar to SW:RHOD_HUMAN 000212 RHO-RELATED GTP-BINDING PROTEIN RHOD (Genbank Accession No.AW003733).

As described in Example 1, DNA chips (U95A, version 2) were used to assay the expression level of the gene for KLAA1048 protein (GenBank Accession No.AB028971). The 1% lower threshold of gene for KIAA1048 protein (GenBank Accession No.AB028971) was 0.66 for the distribution of the control group and the 1% upper threshold of the gene was 1.80 for the distribution of the patient group, and the level of the sample normalized by median was compared with these thresholds, thereby singular determination can be performed in the same manner as Example 1. In the total of 26 samples shown in Tables 4 and 5 (sum of groups C, N and S), no sample had the value of higher than 1.80 and determined to be “normal”. In contrast, seven subjects (N2, N5, S1, S3, S4, S5 and S12) were determined to be “abnormal” for having the values of lower than 0.66. Therefore, as long as the above thresholds are used, false diagnosis such as taking a subject included in the control group as “abnormal” or taking a subject included in the patient groups as “normal” could be avoided.

The same singular determination as in Example 1 was performed on the gene for NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2497327 3′ similar to SW:RHOD_HUMAN 000212 RHO-RELATED GTP-BINDING PROTEIN RHOD (GenBank Accession No.AW003733). The 1% lower threshold of this gene was 0.25 for the distribution of the control group and the 5% upper threshold of the gene was 1.82 for the distribution of the patient group, then value from an unknown sample was normalized to the median and compared with these thresholds. In total of 26 samples shown in Tables 4 and 5 (sum of groups C, N and S), no sample had the value of higher than 1.82 and determined to be “normal”. In contrast, six subjects (S1, S5, S6, S7, S8 and S9) were determined to be “abnormal” for having the value of lower than 0.25. Therefore, as long as the above thresholds are used, false diagnosis such as taking a subject included in the control group as “abnormal” or taking a subject included in the patient groups as “normal” could be avoided.

Using the expression levels on gene for EST-1 protein (GeneBank Accession No.J04101), tKIAA1048 protein (GenBank Accession No.AB028971) and NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2497327 3′ similar to SW:RHOD_HUMAN 000212 RHO-RELATED GTP-BINDING PROTEIN RHOD (GenBank Accession No.AW003733), determinations based on these three genes were combined and any of these determinations was taken as the final determination. As the result, in total of 9 subjects in the normal group, four subjects (C2, C4, C5 and C6) were determined to be “normal.” In the patient group, 14 subjects in 17 subjects were determined to be “abnormal,” except for three subjects (N1, N4 and S10). Therefore, as long as the above criteria are used, false diagnosis such as taking the control group as “abnormal” or taking the patient groups as “normal” could be avoided.

Thus, if the amount of expression in any gene exhibits significant difference (even in a singular gene), a patient can be diagnosed to be schizophrenic. Therefore, diagnosis of schizophrenia can be achieved with higher accuracy.

Example 3 Comprehensive Probability Determination

In this Example, the description will be given about an attempt to provide a more reliable method for diagnosis of schizophrenia. In this Example, plural genes exhibiting abnormal expression level (not within the normal range) in the patient group were by combined and statistical distributions of the expression levels of the genes in the normal control group were taken the into account.

In this Example, the distributions and deviations of the expression levels in normal subjects (unit; the ratio to the median of the DNA chips) are represented for the following 11 genes. Incidentally, since the expression levels of following three genes: 6) platelet-activating factor receptor (GenBank Accession No.D10202), 7) neuregulin 1 isoform HRG-alpha (GenBank Accession No.L41827), and 8) cytosolic component of the nuclear factor of activated T cells (GenBank Accession No.U08015) increased accompanied with schizophrenia, the distributions of the reciprocal numbers were represented for the three genes. The averages, standard deviations, and thresholds of the expression levels in the normal control group as well as the data of samples obtained on the individual genes are represented in Tables 3 and 4.

-   1) inositol polyphosphate-4-phosphatase, type 1, isoform b (GenBank     Accession No.U26398), average±standard deviation=1.39±0.47 -   2) v-ets avian erythroblastosis virus E26 oncogene homolog 1     (GenBank Accession No.J04101), average±standard deviation=3.05±1.70 -   3) NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2489058 3′ similar to     TR:Q15810 Q15810 CLONE 137308 ORF1 (GenBank Accession No.AW006742),     average±standard deviation=1.50±0.41 -   4) Source: Homo sapiens mRNA for KIAA1048 protein, complete cds,     KIAA1048 protein (GenBank Accession No.AB028971), average±standard     deviation=1.22±0.24 -   5) NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2497327 3′ similar     to SW:RHOD_HUMAN 000212 RHO-RELATED GTP-BINDING PROTEIN RHOD     (GenBank Accession No.AW003733), average±standard     deviation=1.08±0.36 -   6) platelet-activating factor receptor (GenBank Accession     No.D10202), average±standard deviation=1.73±3.75 -   7) neuregulin 1 isoform HRG-alpha (GenBank Accession No.L41827),     average±standard deviation=1.43±2.22 -   8) cytosolic component of the nuclear factor of activated T cells,     cytoplasmic, calcineurin-dependent 1 (GenBank Accession No.U08015),     average±standard deviation=1.24±0.69 -   9) Homo sapiens mRNA for KIAA1050 protein (GenBank Accession     No.AB028973), average±standard deviation=0.73±0.47 -   10) Homo sapiens cDNA clone DKFZp564J2262 (GenBank Accession     No.AL036554), average±standard deviation=1.26±0.82 -   11) Angelman Syndrome gene, E6-AP ubiquitin protein ligase 3A     (GenBank Accession No.AF002224), average±standard     deviation=9.96±11.12

As described in Tables 4 and 5, +1 is given if the amount of gene expression to be tested is higher than the amount of average expression in the normal control, whereas −1 is given if the amount of expression is lower than that in the normal control. For example, in the case of N1, +1 is given on the nine genes of 1), 2), 4), 6), 7), 8), 9), 10) and 11) to give the score of +9, −1 is given on two genes of 3) and 5) to give the score of −2, therefore the total score results in +7. Moreover, in the case of N2, +1 is given on the six genes of 2), 3), 5), 6), 8) and 11) to give the score of +6, −1 is given on five genes of 1), 4), 7), 9) and 10) to give the score of −5, therefore the total score results in +1.

As described above, the comparison and the addition of the scores were performed on the 11 genes described above. In the case the total score of a subject was −8 or lower, the subject was determined to be “suffering from schizophrenia (abnormal)” (P<(½)⁸<0.004), whereas in the case the score was between −5 and −7 (P=0.03 to 0.008), the subject was determined to be “pseudo-positive (suspected to be abnormal).” As a result, among 17 patients, it was found that 11 patients (N3, N4, N5, S1, S2, S3, S4, S5, S7, S8 and S9) were determined to be “positive for schizophrenia (abnormal)”, 4 patients (N1, S6, S11 and S12) were determined to be “pseudo-positive for schizophrenia (suspected to be abnormal)”, and two patients (N2, S10) were determined to be “not confirmed”, respectively. Thus, it was demonstrated that a diagnosis could be made on a subject as to whether the subject is suffering from schizophrenia or not with high reliably. To achieve it, the expression levels (including the distribution and the variance) of plural genes were compared with those of the normal control, and the multiplicative values of the probabilities were calculated respectively. As seen from above, simultaneous measurement on the levels of gene expression can be achieved for many sample, use of DNA chips is advantageous.

Example 4 Linear Discriminant Analysis

In this Example, plural genes exhibiting altered expression between the chronic patient group and the acute patient group were used, and the values measured on the chronic and acute patients were treated by weighted linear discriminant, thereby diagnosis of schizophrenia was achieved with higher reliability. The explanation will be made on the Example described in Table 6. TABLE 6 Discriminant score Y Healthy subject C1 8.87 Healthy subject C2 15.02 Healthy subject C3 3.54 Healthy subject C4 12.05 Healthy subject C5 13.00 Healthy subject C6 11.19 Healthy subject C7 12.67 Healthy subject C8 7.07 Healthy subject C9 7.98 Acute patient N1 −2.80 Acute patient N2 −8.65 Acute patient N3 −10.74 Acute patient N4 −11.45 Acute patient N5 −12.55 Chronic patient S1 −12.81 Chronic patient S2 −5.24 Chronic patient S3 −5.12 Chronic patient S4 −16.51 Chronic patient S5 −11.67 Chronic patient S6 −10.66 Chronic patient S7 −4.67 Chronic patient S8 −4.52 Chronic patient S9 −6.30 Chronic patient S10 −17.77 Chronic patient S11 −11.84 Chronic patient S12 −19.31

In this Example, the expression levels of mRNAs of the following genes were measured using the mononuclear cells in peripheral blood derived from a test subject, that is, seven genes (genes 1, 2, 3, 7 and 9) exhibiting altered expression by acute schizophrenia; three genes (genes 4, 8 and 10) exhibiting altered expression by chronic schizophrenia; and two genes (genes 5 and 6) exhibiting altered expression by transition from acute phase to chronic phase of schizophrenia.

-   1) inositol polyphosphate-4-phosphatase, type 1, isoform b (GenBank     Accession No.U26398) The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X1. -   2) v-ets avian erythroblastosis virus E26 oncogene homolog 1     (GenBank Accession No.J04101). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X2. -   3) NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2489058 3′ similar to     TR:Q15810 Q15810 CLONE 137308 ORF1; ESTwr 28gIO X1 (GenBank     Accession No.AW006742). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X3. -   4) Source—Homo sapiens mRNA for KIAA1048 protein, complete cds,     KLAA1048 protein (GenBank Accession No.AB028971). The mRNA level of     the gene on the Gene Chip calibrated by median was represented by     parameter X4. -   5) NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2497327 3′ similar     to SW:RHOD_HUMAN 000212 RHO-RELATED GTP-BINDING PROTEIN RHOD     (GenBank Accession No.AW003733). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X5. -   6) Homo sapiens cDNA clone DKFZp564J2262 (GenBank Accession     No.AL036554). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X6. -   7) Angelman Syndrome gene, E6-AP ubiquitin protein ligase 3A     (GenBank Accession No.AF002224). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X7. -   8) neuregulin 1 isoform HRG-alpha (GenBank Accession No.L41827). The     mRNA level of the gene on the Gene Chip calibrated by median was     represented by parameter X8. -   9) cytosolic component of the nuclear factor of activated T cells     (GenBank Accession No.U08015). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X9. -   10) Homo sapiens mRNA for KIAA1050 protein (GenBank Accession     No.AB028973). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X10.

The expression levels of above-mentioned genes represented by parameters X1 to X10 were used to calculate a discriminant score Y according to the following formula (Formula 1), which was optimized by linear discriminant analysis in advance. Y=9.35×(X1)−0.15×(X2)+7.50×(X3)+8.46×(X4)+0.99×(X5)−0.66×(X6)−0.42×(X7)−5.59×(X8)−3.17×(X9)−1.89×(X10)−13.03  [Formula 1]

As an exemplary trail, the discriminant score Y was calculated for the 26 samples used in the study.

-   (1) Y=8.87 for normal subject C1; 15.02 for normal subject C2; 3.54     for normal subject C3; 12.0 for normal subject C4; 13.00 for normal     subject C5; 11.19 for normal subject C6; 12.67 for normal subject     C7; 7.07 for normal subject C8; and 7.98 for normal subject C9. -   (2) Y=−2.80 for acute patient N1; −8.65 for acute patient N2; −10.74     for acute patient N3; −11.45 for acute patient N4; and −12.55 for     acute patient N5. -   (3) Y=−12.81 for chronic patient S1; −5.24 for chronic patient S2;     −5.12 for chronic patient S3; −16.51 for chronic patient S4; −11.67     for chronic patient S5; −10.66 for chronic patient S6; −4.67 for     chronic patient S7; −4.52 for chronic patient S8; −6.30 for chronic     patient S9; −17.77 for chronic patient S10; −11.84 for chronic     patient S11; and −19.31 for chronic patient S12.

Then in the case the discriminant score Y used as a criteria gave a negative value in a subject, the subject is determined to be schizophrenic; while if discriminant score Y gave a positive value, the subject is determined to be not schizophrenic. Thus, expression levels on plural genes (including those exhibiting altered expression by transition from acute phase to chronic phase of schizophrenia) were measured and the results were treated by weighted linear discriminant analysis. Thereby, diagnosis on whether or not a subject is suffering from schizophrenia could be achieved by with high reliability.

Example 5 Mahalanobis Discriminant Analysis

In this Example, plural genes exhibiting altered expression between the chronic patient group and the acute patient group were used, and the individual expression levels measured on the chronic and acute patients were treated by linear addition with different weights by two manners and the obtained results were plotted in two dimensional coordinate system. Using this method the acute phase and the chronic phase of a patient could be distinguished at once. The explanation will be made using Table 7 and FIG. 1. TABLE 7 Caronical discriminant function coefficient Function 1 2 X1 1.887 −.842 X2 .135 .604 X3 1.652 −.179 X4 1.380 −1.930 X5 .581 1.272 X6 −.092 −.284 X7 −.091 .016 X8 −.853 1.489 X9 −.967 −.887 X10 −.090 1.215 (constant) −2.467 −.783 non standarized coefficient

In this Embodiment, the expression levels of mRNAs of the following genes were measured using the mononuclear cells in peripheral blood derived from a test subject, that is, seven genes (genes 1, 2, 3, 7 and 9) exhibiting altered expression by acute schizophrenia; three genes (genes 4, 8 and 10) exhibiting altered expression by chronic schizophrenia; and two genes (genes 5 and 6) exhibiting altered expression by transition from acute phase to chronic phase of schizophrenia.

-   1) inositol polyphosphate-4-phosphatase, type 1, isoform b (GenBank     Accession No.U26398) The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X1. -   2) v-ets avian erythroblastosis virus E26 oncogene homolog 1     (GenBank Accession No.J04101). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X2. -   3) NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2489058 3′ similar to     TR:Q15810 Q15810 CLONE 137308 ORF1; ESTwr 28gIO X1 (GenBank     Accession No.AW006742). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X3. -   4) Source-Homo sapiens mRNA for KIAA1048 protein, complete cds,     KIAA1048 protein (GenBank Accession No.AB028971). The mRNA level of     the gene on the Gene Chip calibrated by median was represented by     parameter X4. -   5) NCI_CGAP_Kid11 Homo sapiens cDNA clone IMAGE:2497327 3′ similar     to SW:RHOD_HUMAN 000212 RHO-RELATED GTP-BINDING PROTEIN RHOD     (GenBank Accession No.AW003733). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X5. -   6) Homo sapiens cDNA clone DKFZp564J2262 (GenBank Accession     No.AL036554). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X6. -   7) Angelman Syndrome gene, E6-AP ubiquitin protein ligase 3A     (GenBank Accession No.AF002224). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X7. -   8) neuregulin 1 isoform HRG-alpha (GenBank Accession No.L41827). The     mRNA level of the gene on the Gene Chip calibrated by median was     represented by parameter X8. -   9) cytosolic component of the nuclear factor of activated T cells     (GenBank Accession No.U08015). The mRNA level of the gene on the     Gene Chip calibrated by median was represented by parameter X9. -   10) Homo sapiens mRNA for KIAA1050 protein (GenBank Accession     No.AB028973). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X10.

The expression levels of above-mentioned genes represented by parameters X1 to X10 were used and the position of the test subject in a coordinate system (X, Y) was calculated according to the following formulas (Formula 2, Formula 3), which was optimized by linear discriminant analysis in advance. X=1.187×(X1)+0.135×(X2)+1.652×(X3)+1.380×(X4)+0.581×(X5)−0.092×(X6)−0.091×(X7)−0.853×(X8)−0.967×(X9)−0.090×(X10)−2.467  [Formula 2] Y=−0.842×(X1)+0.604×(X2)−0.179×(X3) −1.930×(X4)+1.272×(X5)−0.284×(X6)+0.016×(X7)+1.489×(X8)−0.887×(X9)+1.215×(X10)−0.783  [Formula 3]

As an exemplary trial, calculation was performed for the 26 samples used in the study. As the result, as shown in FIG. 1, it was revealed that the plots from each groups, i.e. the normal subject group, the acute schizophrenic patient group and the chronic schizophrenic patient group, gathered at certain regions of the coordinate system. Therefore, by adopting following criteria, determination of “acute schizophrenia,” “chronic schizophrenia,” and “non-schizophrenia” could be made for all of the samples. Meanwhile, those in other region could not be determined.

-   -   −1.5<X<1 & 1.1<Y<5 : acute schizophrenia     -   −4<X<0 & −3<Y<1.1: chronic schizophrenia     -   1<X<4 & −2<Y<2: non-schizophrenia

Thus, the expression levels of plural genes (including those exhibiting altered expression at transition from acute phase to chronic phase of schizophrenia) were measured and results were treated by weighted linear addition according to plural manners. Thereby, diagnosis on whether or not a subject is suffering from schizophrenia could be achieved by with high reliability.

Example 6 Analysis by mRNA Level of Kinase/Phosphatase

The genes represented in Table 1 were those exhibiting altered mRNA expression by schizophrenia in mononuclear cells of patients and the functions of the genes were classified. As the result, it was revealed that the largest part of the genes was identified to be kinase/phosphatase, which are responsible for phosphorylation or de-phosphorylation of moleculars such as proteins. From this phenomenon, it was suggested that there may be some abnormalities on phosphorylation state of the mononuclear cells in schizophrenia. Paying attention to this phenomenon, the inventors selected the sixteen genes involved in phosphorylation reactions (kinase/phosphatase) described below. Then mRNA level alteration was investigated for the genes in patients.

-   1) Ndr serine threonine protein kinase (GenBank Accession     No.Z35102). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X1. inositol     polyphosphate-4-phosphatase, type 1, isoform b (GenBank Accession     No.U26398). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X2. -   2) janus kinase 1 (GenBank Accession No.M64174). Its mRNA level on     the gene chip based on the corrected median is represented by     parameter X2. -   3) inositol polyphosphate-4-phosphatase, type 1, isoform b (GenBank     Accession No.U96919). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X3. -   4) protein kinase, AMP-activated, alpha 1 catalytic subunit (GenBank     Accession No.AB022017). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X4. -   5) protein kinase C, nu (GenBank Accession No.AB015982). The mRNA     level of the gene on the Gene Chip calibrated by median was     represented by parameter X5. -   6) MEK kinase (GenBank Accession No.U29671). The mRNA level of the     gene on the Gene Chip calibrated by median was represented by     parameter X6. -   7) tyrosine kinase (GenBank Accession No.U07794). The mRNA level of     the gene on the Gene Chip calibrated by median was represented by     parameter X7. -   8) serine/threonine-protein kinase PRP4 homolog (GenBank Accession     No.U48736). The mRNA level of the gene on the Gene Chip calibrated     by median was represented by parameter X8. -   9) ribosomal protein S6 kinase, 90 kD, polypeptide 3 (GenBank     Accession No.U08316). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X9. -   10) SNF1-like protein kinase (GenBank Accession No.U57452). The mRNA     level of the gene on the Gene Chip calibrated by median was     represented by parameter X10. -   11) protein-tyrosine phosphatase (GenBank Accession No.D13540). The     mRNA level of the gene on the Gene Chip calibrated by median was     represented by parameter X11. -   12) interferon-inducible RNA-dependent protein kinase (GenBank     Accession No.U50648). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X12. -   13) protein kinase, cAMP-dependent, catalytic, alpha (GenBank     Accession No.X07767). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X13. -   14) PCTAIRE protein kinase 1 (GenBank Accession No.X66363). The mRNA     level of the gene on the Gene Chip calibrated by median was     represented by parameter X14. -   15) branched chain alpha-ketoacid dehydrogenase kinase (GenBank     Accession No.AF026548). The mRNA level of the gene on the Gene Chip     calibrated by median was represented by parameter X15. -   16) phosphomevalonate kinase (GenBank Accession No.L77213). The mRNA     level of the gene on the Gene Chip calibrated by median was     represented by parameter X16.

In this Example, linear discriminant analysis was performed on an acute patient group including six patients (N1-N6), chronic patient group including 12 patients (S1-S12), and normal group including 12 normal subjects (C1-C12). Then alteration of the mRNA level was determined on the above-mentioned enzymes. In concrete, the mRNA signal intensities of the genes on the Gene Chip were assigned as parameters X1 to X16, and a discriminant score Y was calculated according to the following formula (Formula 4), which was optimized by linear discriminant analysis in advance. Y=−4.60X1−5.77X2+7.74X3−13.9X4+24.2X5+4.11X6+3.20X7−7.41X8+5.76X9−1.06X10+34.1X11+0.15X12+4.16X13−2.51X14+14.9X15−2.85X16+3.50  [Formula 4]

The results are shown in Table 8 and FIG. 2. As seen from FIG. 2, the mRNA levels of the genes encoding the enzymes responsible for phosphorylation of mononuclear cells were altered in schizophrenic patients (S1-S12 and N1-N6). As the result, mRNA levels in schizophrenic patients were apparently distinguishable from those of normal subjects (C1-C12). TABLE 8 Subject Discriminant score C1 −3.1574 C10 −3.84504 C11 −5.49943 C12 −4.73543 C2 −4.90849 C3 −3.73479 C4 −5.41805 C5 −4.27379 C6 −5.45122 C7 −3.9983 C8 −4.78686 C9 −4.95949 N1 1.8629 N2 3.14171 N3. 3.47818 N4 2.33664 N5 3.04534 N6 1.88635 S1 3.14728 S10 4.12939 S11 5.0998 S12 1.68138 S2 4.01308 S3 2.60176 S4 4.45117 S5 2.4072 S6 1.22822 S7 2.21729 S8 4.90192 S9 3.13867 Mean value S.D. C −4.56402 0.758766 N   2.625187 0.690093 S   3.25143 1.269113

Example 7 Investigations on Patients with Other Psychiatric Diseases

As to patients suffering from depression or panic syndrome (B1-B6) which may exhibit symptoms similar to schizophrenia, using the linear discriminant (Formula 4) shown in the Example 6, gene expression profiling was performed on genes of mononuclear cells in blood of the patients, using the DNA Chips by the method as described above. In the same manner as in Example 6, the mRNA signal intensities encoding 16 enzymes involved in phosphorylation reaction were applied to the same formula (Formula 4) used in Example 6 to provide a discriminant score Y. The results are shown in Table 9.

As shown in Table 9, in five patients except for patient B3, all of the discriminant scores were negative values, thus the patients were determined to be not suffering from schizophrenia. As to the patient B3, the Y score was +1.6 and exhibited weak positive. The result of this biological test may suggest the possibility that the patient B3 is suffering from schizophrenia. As seen from above, the discriminant according to Formula 4, paying attention to the mRNA levels of the genes encoding kinases/phosphatases, may be useful for determination of psychiatric diseases including schizophrenia. TABLE 9 Subject Discrimant score B1 −4.37615 B2 −4.96375 B3 1.60492 B4 −4.34437 B5 −2.23161 B6 −1.29941

Example 8 Mahalanobis Discriminant Analysis

In this Example, the mRNA intensities of the genes encoding the enzymes involved in phosphorylation or de-phosphorylation (kinases/phosphatases) were measured like Example 6 and two primary discriminant functions were determined using Mahalanobis cluster analysis. The discriminant scores of each sample were plotted on a two-dimensional plane, then the results were discriminated into three groups, i.e. acute patient group (N1-N6), chronic patient group (S1-S12) and normal group (C1-C12). The mRNA expression intensities (X1 to X16) were obtained for the 16 genes in the Example 6 on a DNA Chip, and the results were applied to the following two linear equations (Formula 5 and Formula 6). The coordinate consisted of (X, Y) in the Table 10 and in the Table 11, and the positions in the coordinate were calculated for the test subjects. The results from the schizophrenic patients (S1-S12 and N1-N6: the same as in Table 8) and those from the normal subjects (C1-C12) were shown in Table 10. Moreover, the results from the six patients (B1-B6: the same as in Table 9) suffering from psychiatric diseases other than schizophrenia were shown in Table 11. The results shown in Table 10 and Table 11 are plotted on a two-dimensional discrimination diagram shown in FIG. 3. In FIG. 3, the solid column represents the results from chronic schizophrenic patients, the open column represents those from acute schizophrenic patients, and the hatched column represents those from normal subjects. X=−4.32X1−6.96X2−0.31X3−12.4X4+14.4X5+4.84X6+2.97X7−21.5X8+8.11X9+8.30X10+46.8X11−0.89X12+4.26X13−2.48X14+16.7X15−4.97X16+7.03  [Formula 5] Y=−1.96X1−0.30X2+13.8X3−6.74X4+21.8X5+0.37X6+1.42X7+17.1X8−1.31X9−13.4X10−6.13X11+1.50X12+1.26X13−0.90X14+2.48X15+1.99X16−3.72  [Formula 6]

TABLE 10 Subject Discrimant score X Discrimant score Y C1 −3.31117 −0.86085 C10 −5.52444 1.02784 C11 −6.2157 −0.87543 C12 −5.15963 −1.02175 C2 −5.15608 −1.3264 C3 −4.24532 −0.561 C4 −6.69962 −0.06117 C5 −4.37362 −1.31594 C6 −5.35035 −1.996 C7 −5.77044 1.10472 C8 −5.55691 −0.55805 C9 −4.76531 −1.95843 N1 0.04866 3.15851 N2 0.48305 4.76873 N3. 1.74519 3.59529 N4 0.44795 3.42336 N5 1.44364 3.26529 N6 0.46093 2.62548 S1 4.27598 −0.49912 S10 6.49481 −1.88558 S11 5.64561 0.97659 S12 3.5928 −2.08721 S2 5.83667 −1.17126 S3 4.23527 −1.38722 S4 6.12612 −0.81531 S5 5.07678 −2.89504 S6 2.49265 −1.34124 S7 3.75289 −1.38186 S8 5.50818 0.8251 S9 4.46141 −0.77205

TABLE 11 Discrimant score X Discrimant score Y B1 −6.84479 1.94521 B2 −6.09437 −0.11655 B3 0.93432 1.47941 B4 −2.07503 −4.63643 B5 −4.18643 1.96029 B6 −1.44387 −0.24133

As shown by the sets of circles shown in FIG. 3, the scores from “acute schizophrenia group” “chronic schizophrenia group” and “normal group” gathered in a certain region of the graph, therefore, the three groups were completely distinguishable from each other. In addition, the blind data were obtained from the group of patients suffering from psychiatric diseases other than schizophrenia (B1-B6) and the data were also treated by the same Formulas (Formula 5 and Formula 6). The results were plotted in the same figure by the “X” marks, to reveal that the patients do not belong to the regions corresponding to the “acute schizophrenia group” “chronic schizophrenia group” and “normal group” described above. This suggests that the discriminant is also useful for the discrimination of psychiatric diseases other than schizophrenia.

The method of the invention provides a group of genes useful for objective diagnosis on whether or not a test subject is suffering from schizophrenia in non-invasive manner. Therefore, development of a DNA chip containing genes effective for diagnosis of schizophrenia may be achieved utilizing the knowledge obtained in this invention. 

1. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, measuring gene expression profile in said test subject by a DNA micro-array or a DNA chip, determining whether the quantified level in said test subject exhibits statistical significant alteration or not in comparison with the gene expression profile in healthy subjects or in schizophrenic patients to diagnose whether said test subject suffers from schizophrenia or not.
 2. A DNA micro-array or a DNA chip available in the method according to claim
 1. 3. The DNA micro-array or the DNA chip according to claim 2, which immobilized with nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (152) with GenBank No. described in brackets. (1) Homo sapiens cDNA, 3′ end/clone=IMAGE-2329930, EST wd33c06.x1 (Genbank No. A1677689) (2) Bcl-XI (Genbank No. Z23115) (3) ZNF37A mRNA for zinc finger (Genbank No. X69115) (4) HSCCG1 Human X chromsome mRNA for CCG1 protein inv. in cell proliferation (Genbank No. X07024) (5) Interferon receptor type 2 (IFNAR2) (Genbank No. L42243) (6) Guanine Nucleotide Exchange Factor 1 (Genbank No. HG960-HT960) (7) Glucosamine-6-sulphatase precursor (Genbank No. Z12173) (8) MACH-beta-1 protein (Caspase 8)(Genbank No. X98176) (9) EST 15all Homo sapiens cDNA/gb=W25921/gi=1306044/ug=Hs.164036/len=723 (Genbank No. W25921) (10) Ndr protein kinase (Genbank No. Z35102) (11) 14-3-3 protein (Genbank No. U28964) (12) RbAp48 mRNA encoding retinoblastoma binding protein (Genbank No. X74262) (13) SNAP23B protein (Genbank No. Y09568) (14) Inhibitory protein for potassium-induced deficiency type 1 (SKD1 homolog) (Genbank No. AF038960) (15) Homo sapiens cDNA, 3′ end/clone=IMAGE-2509049, ETS wt31b09.x1 (Genbank No. A1955897) (16) Utrophin (Genbank No. X69086) (17) cdc2-related protein kinase (Genbank No. M80629) (18) Calmodulin type 1 (CALM1) (Genbank No. U12022) (19) Rb2/p130 protein (Genbank No. X74594) (20) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (21) GTP-binding protein RAB6 (Genbank No. M28212) (22) C1q/MBL/SPA receptor C1qR(p) (Genbank No. U94333) (23) Zinc finger/leucine zipper protein (AF10)(Genbank No. U13948) (24) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (25) Inositol polyphosphate 4-phosphatase (Genbank No. U26398) (26) Cytohesin binding protein HE (Genbank No. AF068836) (27) Cas like protein for enhancer of filamentation (HEF1) (Genbank No. L43821) (28) Rho GTPase-activated protein type 5 (p190-B) (Genbank No. U17032) (29) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (30) Syntaxin 16 (Genbank No. AF038897) (31) Cyclophilin-Related Protein (Genbank No. HG846-HT846) (32) Natural killer-tumor recognition sequence (Genbank No. L04288) (33) Integrin alpha 6B (CD49f) (Genbank No. S66213) (34) Homo sapiens clone 24629 mRNA sequence (Genbank No. AF052160) (35) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (36) mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585nt] (Genbank No. S79325) (37) Glucose transporter pseudogene (Genbank No. M55536) (38) Nuclear receptor intermediary activation factor 2 (TIF2) (Genbank No. X97674) (39) CRE-BP1 transcription factor (Genbank No. U16028) (40) Topoisomerase type II (Topo II) (Genbank No. M27504) (41) Nuclear respiratory factor-2 subunit alpha (Genbank No. U13044) (42) PAC clone DJ1185107 from 7q11.23-q21 RP5-1185I07 (Genbank No. AC004990) (43) Cyclin T2b (Genbank No. AF048732) (44) Zinc finger protein type C3H (MBLL) (Genbank No. AF061261) (45) MEK kinase (Mekk) (Genbank No. U29671) (46) Rod1 (Genbank No. AB023967) (47) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (48) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (49) pre-mRNA cleavage factor I subunit Im (Genbank No. AJ001810) (50) Homo sapiens cDNA, 3′ end/clone=IMAGE-2512364, EST wt65e11.x1 (Genbank No. A1961669) (51) Disintegrin-metalloprotease (Genbank No. Z48579) (52) ADP-ribosylation factor no.6 (ARF6) (Genbank No. AF047432) (53) Helicase like protein 2 containing DEAD/H box (DDX14) (Genbank No. U50553) (54) p300/CBP-associated factor (P/CAF) (Genbank No. U57317) (55) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (56) Cyclin G1 (Genbank No. X77794) (57) Guanine binding protein type q (Gaq) (Genbank No. U43083) (58) Trinucleotide repeat CGG-DNA binding protein p20-CGGBP (CGGBP) (Genbank No. AF094481) (59) Integrin alpha 4 subunit (CD49d) (Genbank No. L12002) (60) Chromosome 5q21-22, clone-A3-A (Genbank No. AB002450) (61) Unknown protein of uterine endometrium (Genbank No. X77723) (62) Transcription factor ISGF-3 (STAT91) (Genbank No. M97935) (63) Human PAC clone DJ525N14 from Xq23 RP3-525N14 (Genbank No. AC002086) (64) SH2 domain protein 1A isoform B (SH2D1A) (Genbank No. AF100539) (65) Killer cell lectin-like receptor NKG2F (Genbank No. AJ001683) (66) Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) (Genbank No. U13896) (67) Human SNF1-like protein kinase (Genbank No. U57452) (68) Human DNA for c-ets-1 proto-oncogene (Genbank No. X14798) (69) EAR-1r (Genbank No. D16815) (70) Guanine nucleotide regulatory protein (G alpha 13) (Genbank No. L22075) (71) Retinoblastoma susceptibility protein (RB1) (Genbank No. L49229) (72) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (73) EST 14e9 Homo sapiens cDNA (Genbank No. W25874) (74) MDM2-like p53-binding protein (MDMX) (Genbank No. AF007111) (75) Homo sapiens cDNA, 5′ end/clone=IMAGE-360208, EST ze27c09.r1 (Genbank No. AA013087) (76) Erythroblastosis virus oncogene homolog 1 (ets-1) (Genbank No. J04101) (77) HUMM9, Man9-mannosidase (Genbank No. X74837) (78) Kinesin/heavy chain SB (Genbank No. X65873) (79) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (80) Interferon regulatory factor-2 (IRF-2) (Genbank No. X15949) (81) Homo sapiens cDNA, 3′ end/clone=IMAGE-1722789, EST qd04h11.x1 (Genbank No. AI189226) (82) Chondroitin sulfate proteoglycan PG-M (bursicon) (Genbank No. D32039) (83) Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) (Genbank No. AL049962) (84) EST36b3 Homo sapiens cDNA (Genbank No. W27675) (85) Homo sapiens cDNA, 3′ end/clone=IMAGE-2489058, EST wr28g10.x1 (Genbank No. AW006742) (86) Homo sapiens cDNA, 3′ end/clone=IMAGE-815515, EST aa 38b10.s1 (Genbank No. AA457029) (87) c-myc proto-oncogene (MYCL2) (Genbank No. J03069) (88) Mature T cell proliferation factor c6.1B gene; MTCP1 gene (Genbank No. Z24459) (89) Homo sapiens mRNA for KIAA0797 protein (Genbank No. AB018340) (90) N-ras (Genbank No. X02751) (91) WD repeat protein HAN11 (Genbank No. U94747) (92) Homo sapiens mRNA for KIAA1048 protein (Genbank No. AB028971) (93) Homo sapiens mRNA for KIAA0454 protein (Genbank No. AB007923) (94) Cystine/glutamate transporter (Genbank No. AB026891) (95) Microsomal stress 70 protein ATPase core (stch) (Genbank No. U04735) (96) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (97) Homo sapiens cDNA, 5′ end/clone=IMAGE-2497327 (Genbank No AW003733) (98) Homo sapiens cDNA, 5′ end/clone=IMAGE-487691 (Genbank No. AA058762) (99) Monoamine oxidase B (MAOB) (Genbank No. M69177) (100) lipocortin-III (annexins A3) (Genbank No. M20560) (101) Homo sapiens chromosome 1 specific transcript KIAA0508 (Genbank No. AB007977) (102) Platelet-activating factor receptor (Genbank No. D10202) (103) EST DKFZp586A2224_s1 Homo sapiens cDNA (Genbank No. AL048308) (104) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (105) Gelsolin; macrophage capping protein; villin (Genbank No. M94345) (106) EST 31c9 Homo sapiens cDNA (Genbank No. W27466) (107) Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) (Genbank No. Y15909) (108) Insulin receptor precursor (Genbank No. X02160) (109) Heregulin type 1 (HRG alpha) (Genbank No. L1827) (110) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (111) Electron transfer flavoprotein beta subunit (Genbank No. X71129) (112) p160 (Genbank No. U88153) (113) Calciceurin dependently activated T cell nuclear factor (NF-Atc) (Genbank No. U08015) (114) Homo sapiens mRNA for KIAA0563 protein (Genbank No. AB011135) (115) Vscular smooth muscle alpha-actin (Genbank No. X13839) (116) Rad17-like protein (RAD17) (Genbank No. AF076838) (117) Homo sapiens cDNA, 3′ end/clone=IMAGE-2394055, EST wi54d04.x1 (Genbank No. A1762213) (118) Homo sapiens cDNA, 3 end/clone=IMAGE-979142, EST ni38e08.s1 (Genbank No. AA522537) (119) Human T54 protein (T54) (Genbank No. U66359) (120) Acyl-CoA dehydrogenase; SCAD gene (Genbank No. Z80345) (121) Phosphomevalonate kinase (Genbank No. L77213) (122) Drebrin E (Genbank No. D17530) (123) Receptor protein-tyrosine kinase EphA4 (HEK8) (Genbank No. L36645) (124) Tob family transducer ERBB2,2 (Genbank No. D64109) (125) Homo sapiens cDNA, 3 end/clone=IMAGE-1657913, ESTox31b09.s1 (Genbank No. A1039144) (126) Homogentisate 1,2-dioxygenase (Genbank No. AF000573) (127) MFH-proliferation sequence (MASL1) (Genbank No. AB016816) (128) Homo sapiens mRNA for KIAA0994 protein (Genbank No. AB023211) (129) Homo sapiens cDNA, 3 end/clone=IMAGE-826408, EST aa71e09.s1 (Genbank No. AA521060) (130) Neutrophil cytoplasmic factor type 4 (p40phox) (Genbank No. X77094) (131) Mucin 5b (Genbank No. HG2689-HT2785) (132) Homo sapiens cDNA, 3 end/clone=IMAGE-965972, EST nh92c11.s1 (Genbank No. AA528252) (133) Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) (Genbank No. M14648) (134) Cluster Incl AL049435:Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220 (Genbank No. AL049435) (135) Homo sapiens (clone S164) mRNA, 3 end of cds/cds (Genbank No. L40392) (136) mRNA for KIAA1009 protein (Genbank No. AB023226) (137) mRNA for KIAA0716 protein (Genbank No. AB018259) (138) Vanin-like gene; vnn1 gene; VNN1 protein (Genbank No. AJ132099) (139) Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 (Genbank No. AC004893) (140) Homo sapiens mRNA for KIAA1050 protein (Genbank No. AB028973) (141) Human Chromosome 16 BAC clone CIT987SK-A-270G1 (Genbank No. AF001549) (142) Transcriptional factor TREB protein (Genbank No. X55544) (143) Homo sapiens mRNA for KIAA0548 protein (Genbank No. AB011120) (144) p300; transcriptional adaptor protein; E1A-binding protein (Genbank No. U01877) (145) Integrin alpha E precursor (CD103) (L25851) (146) Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1 (Genbank No. AI148772) (147) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 (Genbank No. AL109724) (148) Defensins alpha 3 (Genbank No. L12691) (149) Homo sapiens cDNA, 5′ end/clone=DKFZp564J2262-r1 (Genbank No. AL036554) (150) Elastase/medullasin (Genbank No. M34379) (151) Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) (Genbank No. AF002224) (152) Skeletal muscle 165 kD protein (Genbank No. X69089)
 4. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing nucleic acid from said subject, measuring the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and determining alteration of the quantified level(s) of the gene(s) in said test subject is statistically significant in comparison with the quantified level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or schizophrenic patients, thereby diagnosing whether said subject is suffering from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (152) with GenBank No. described in brackets. (1) Homo sapiens cDNA, 3′ end/clone=IMAGE-2329930, EST wd33c06.x1 (Genbank No. AI677689) (2) Bcl-Xl (Genbank No. Z23115) (3) ZNF37A mRNA for zinc finger (Genbank No. X69115) (4) HSCCG1 Human X chromsome mRNA for CCG1 protein inv. in cell proliferation (Genbank No. X07024) (5) Interferon receptor type 2 (IFNAR2) (Genbank No. L42243) (6) Guanine Nucleotide Exchange Factor 1 (Genbank No. HG960-HT960) (7) Glucosamine-6-sulphatase precursor (Genbank No. Z12173) (8) MACH-beta-1 protein (Caspase 8)(Genbank No. X98176) (9) EST 15a11 Homo sapiens cDNA/gb=W25921/gi=1306044/ug=Hs.164036/len=723 (Genbank No. W25921) (10) Ndr protein kinase (Genbank No. Z35102) (11) 14-3-3 protein (Genbank No. U28964) (12) RbAp48 mRNA encoding retinoblastoma binding protein (Genbank No. X74262) (13) SNAP23B protein (Genbank No. Y09568) (14) Inhibitory protein for potassium-induced deficiency type 1 (SKD1 homolog) (Genbank No. AF038960) (15) Homo sapiens cDNA, 3′ end/clone=IMAGE-2509049, ETS wt31b09.x1 (Genbank No. A1955897) (16) Utrophin (Genbank No. X69086) (17) cdc2-related protein kinase (Genbank No. M80629) (18) Calmodulin type 1 (CALM1) (Genbank No. U12022) (19) Rb2/p130 protein (Genbank No. X74594) (20) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (21) GTP-binding protein RAB6 (Genbank No. M28212) (22) Clq/MBL/SPA receptor C1qR(p) (Genbank No. U94333) (23) Zinc finger/leucine zipper protein (AF10)(Genbank No. U13948) (24) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (25) Inositol polyphosphate 4-phosphatase (Genbank No. U26398) (26) Cytohesin binding protein HE (Genbank No. AF068836) (27) Cas like protein for enhancer of filamentation (HEF1) (Genbank No. L43821) (28) Rho GTPase-activated protein type 5 (p190-B) (Genbank No. U17032) (29) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (30) Syntaxin 16 (Genbank No. AF038897) (31) Cyclophilin-Related Protein (Genbank No. HG846-HT846) (32) Natural killer-tumor recognition sequence (Genbank No. L04288) (33) Integrin alpha 6B (CD49f) (Genbank No. S66213) (34) Homo sapiens clone 24629 mRNA sequence (Genbank No. AF052160) (35) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (36) mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585nt] (Genbank No. S79325) (37) Glucose transporter pseudogene (Genbank No. M55536) (38) Nuclear receptor intermediary activation factor 2 (TIF2) (Genbank No. X97674) (39) CRE-BP1 transcription factor (Genbank No. U16028) (40) Topoisomerase type II (Topo II) (Genbank No. M27504) (41) Nuclear respiratory factor-2 subunit alpha (Genbank No. U13044) (42) PAC clone DJ1185107 from 7q11.23-q21 RP5-1185107 (Genbank No. AC004990) (43) Cyclin T2b (Genbank No. AF048732) (44) Zinc finger protein type C3H (MBLL) (Genbank No. AF061261) (45) MEK kinase (Mekk) (Genbank No. U29671) (46) Rod1 (Genbank No. AB023967) (47) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (48) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (49) pre-mRNA cleavage factor I subunit Im (Genbank No. AJ001810) (50) Homo sapiens cDNA, 3′ end/clone=IMAGE-2512364, EST wt65e11.x1 (Genbank No. AI961669) (51) Disintegrin-metalloprotease (Genbank No. Z48579) (52) ADP-ribosylation factor no.6 (ARF6) (Genbank No. AF047432) (53) Helicase like protein 2 containing DEAD/H box (DDX14) (Genbank No. U50553) (54) p300/CBP-associated factor (P/CAF) (Genbank No. U57317) (55) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (56) Cyclin G1 (Genbank No. X77794) (57) Guanine binding protein type q (Gaq) (Genbank No. U43083) (58) Trinucleotide repeat CGG-DNA binding protein p20-CGGBP (CGGBP) (Genbank No. AF094481) (59) Integrin alpha 4 subunit (CD49d) (Genbank No. L12002) (60) Chromosome 5q21-22, clone-A3-A (Genbank No. AB002450) (61) Unknown protein of uterine endometrium (Genbank No. X77723) (62) Transcription factor ISGF-3 (STAT91) (Genbank No. M97935) (63) Human PAC clone DJ525N14 from Xq23 RP3-525N14 (Genbank No. AC002086) (64) SH2 domain protein 1A isoform B (SH2D1A) (Genbank No. AF100539) (65) Killer cell lectin-like receptor NKG2F (Genbank No. AJ001683) (66) Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) (Genbank No. U13896) (67) Human SNF1-like protein kinase (Genbank No. U57452) (68) Human DNA for c-ets-1 proto-oncogene (Genbank No. X14798) (69) EAR-1r (Genbank No. D16815) (70) Guanine nucleotide regulatory protein (G alpha 13) (Genbank No. L22075) (71) Retinoblastoma susceptibility protein (RB1) (Genbank No. L49229) (72) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (73) EST 14e9 Homo sapiens cDNA (Genbank No. W25874) (74) MDM2-like p53-binding protein (MDMX) (Genbank No. AF007111) (75) Homo sapiens cDNA, 5′ end/clone=IMAGE-360208, EST ze27c09.r1 (Genbank No. AA013087) (76) Erythroblastosis virus oncogene homolog 1 (ets-1) (Genbank No. J04101) (77) HUMM9, Man9-mannosidase (Genbank No. X74837) (78) Kinesin/heavy chain 5B (Genbank No. X65873) (79) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (80) Interferon regulatory factor-2 (IRF-2) (Genbank No. X15949) (81) Homo sapiens cDNA, 3′ end/clone=IMAGE-1722789, EST qd04h11.x1 (Genbank No. AI189226) (82) Chondroitin sulfate proteoglycan PG-M (bursicon) (Genbank No. D32039) (83) Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) (Genbank No. AL049962) (84) EST36b3 Homo sapiens cDNA (Genbank No. W27675) (85) Homo sapiens cDNA, 3′ end/clone=IMAGE-2489058, EST wr28g10.x1 (Genbank No. AW006742) (86) Homo sapiens cDNA, 3′ end/clone=IMAGE-815515, EST aa 38b10.s1 (Genbank No. AA457029) (87) c-myc proto-oncogene (MYCL2) (Genbank No. J03069) (88) Mature T cell proliferation factor c6.1B gene; MTCP1 gene (Genbank No. Z24459) (89) Homo sapiens mRNA for KIAA0797 protein (Genbank No. AB018340) (90) N-ras (Genbank No. X02751) (91) WD repeat protein HAN11 (Genbank No. U94747) (92) Homo sapiens mRNA for KIAA1048 protein (Genbank No. AB028971) (93) Homo sapiens mRNA for KIAA0454 protein (Genbank No. AB007923) (94) Cystine/glutamate transporter (Genbank No. AB026891) (95) Microsomal stress 70 protein ATPase core (stch) (Genbank No. U04735) (96) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (97) Homo sapiens cDNA, 5′ end/clone=IMAGE-2497327 (Genbank No AW003733) (98) Homo sapiens cDNA, 5′ end/clone=IMAGE-487691 (Genbank No. AA058762) (99) Monoamine oxidase B (MAOB) (Genbank No. M69177) (100) lipocortin-III (annexins A3) (Genbank No. M20560) (101) Homo sapiens chromosome 1 specific transcript KIAA0508 (Genbank No. AB007977) (102) Platelet-activating factor receptor (Genbank No. D10202) (103)EST DKFZp586A2224_s1 Homo sapiens cDNA (Genbank No. AL048308) (104) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (105) Gelsolin; macrophage capping protein; villin (Genbank No. M94345) (106) EST 31c9 Homo sapiens cDNA (Genbank No. W27466) (107) Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) (Genbank No. Y15909) (108) Insulin receptor precursor (Genbank No. X02160) (109) Heregulin type 1 (HRG alpha) (Genbank No. L41827) (110) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (111) Electron transfer flavoprotein beta subunit (Genbank No. X71129) (112) p160 (Genbank No. U88153) (113) Calciceurin dependently activated T cell nuclear factor (NF-Atc) (Genbank No. U08015) (114) Homo sapiens mRNA for KIAA0563 protein (Genbank No. AB011135) (115) Vscular smooth muscle alpha-actin (Genbank No. X13839) (116) Rad17-like protein (RAD17) (Genbank No. AF076838) (117) Homo sapiens cDNA, 3′ end/clone=IMAGE-2394055, EST wi54d04.x1 (Genbank No. AI762213) (118) Homo sapiens cDNA, 3 end/clone=IMAGE-979142, EST ni38e08.s1 (Genbank No. AA522537) (119) Human T54 protein (T54) (Genbank No. U66359) (120) Acyl-CoA dehydrogenase; SCAD gene (Genbank No. Z80345) (121) Phosphomevalonate kinase (Genbank No. L77213) (122) Drebrin E (Genbank No. D17530) (123) Receptor protein-tyrosine kinase EphA4 (HEK8) (Genbank No. L36645) (124) Tob family transducer ERBB2,2 (Genbank No. D64109) (125) Homo sapiens cDNA, 3 end/clone=IMAGE-1657913, ESTox31b09.s1 (Genbank No. A1039144) (126) Homogentisate 1,2-dioxygenase (Genbank No. AF000573) (127) MFH-proliferation sequence (MASL1) (Genbank No. AB016816) (128) Homo sapiens mRNA for KIAA0994 protein (Genbank No. AB023211) (129) Homo sapiens cDNA, 3 end/clone=IMAGE-826408, EST aa7le09.s1 (Genbank No. AA521060) (130) Neutrophil cytoplasmic factor type 4 (p40phox) (Genbank No. X77094) (131) Mucin 5b (Genbank No. HG2689-HT2785) (132) Homo sapiens cDNA, 3 end/clone=IMAGE-965972, EST nh92c11.s1 (Genbank No. AA528252) (133) Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) (Genbank No. M14648) (134) Cluster Incl AL049435:Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220 (Genbank No. AL049435) (135) Homo sapiens (clone S164) mRNA, 3 end of cds/cds (Genbank No. L40392) (136) mRNA for KIAA1009 protein (Genbank No. AB023226) (137) mRNA for KIAA0716 protein (Genbank No. AB018259) (138) Vanin-like gene; vnn1 gene; VNN1 protein (Genbank No. AJ132099) (139) Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 (Genbank No. AC004893) (140) Homo sapiens mRNA for KIAA1050 protein (Genbank No. AB028973) (141) Human Chromosome 16 BAC clone CIT987SK-A-270G1 (Genbank No. AF001549) (142) Transcriptional factor TREB protein (Genbank No. X55544) (143) Homo sapiens mRNA for KIAA0548 protein (Genbank No. AB011120) (144) p300; transcriptional adaptor protein; E1A-binding protein (Genbank No. U01877) (145) Integrin alpha E precursor (CD103) (L25851) (146) Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1 (Genbank No. A1148772) (147) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 (Genbank No. AL109724) (148) Defensins alpha 3 (Genbank No. L12691) (149) Homo sapiens cDNA, 5′ end/clone=DKFZp564J2262-r1 (Genbank No. AL036554) (150) Elastase/medullasin (Genbank No. M34379) (151) Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) (Genbank No. AF002224) (152) Skeletal muscle 165 kD protein (Genbank No. X69089)
 5. The method according to claim 4, wherein expression levels of 2 to 50 kinds of genes derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia are utilized as an index for diagnosing whether the test subject suffers from schizophrenia or not.
 6. The method according to claim 4, wherein expression levels of 2 to 20 kinds of genes derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia are utilized as an index for diagnosing whether the test subject suffers from schizophrenia or not.
 7. The method according to claim 4, wherein expression levels of 2 to 10 kinds of genes derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia are utilized as an index for diagnosing whether the test subject suffers from schizophrenia or not.
 8. The method according to claim 4, wherein expression levels of 1 kind of gene derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is utilized as an index for diagnosing whether the test subject suffers from schizophrenia or not.
 9. A method for analyzing whether or not the expression level(s) of nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in a test subject is statistically excluded from the range of the expression level(s) of the nucleic acid(s) in schizophrenic patients, the method comprising the steps of; obtaining mononuclear cells in blood containing nucleic acid from said test subject, measuring the content of at least one nucleic acid selected from the group consisting of the nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or the nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and comparing the determined level(s) in said test subject with the determined level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or in schizophrenic patients to analyze whether the alteration of said determined level in said test subject is statistically significant or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (152) with GenBank No. described in brackets. (1) Homo sapiens cDNA, 3′ end/clone=IMAGE-2329930, EST wd33c06.x1 (Genbank No. AI677689) (2) Bcl-Xl (Genbank No. Z23115) (3) ZNF37A mRNA for zinc finger (Genbank No. X69115) (4) HSCCG1 Human X chromsome mRNA for CCG1 protein inv. in cell proliferation (Genbank No. X07024) (5) Interferon receptor type 2 (IFNAR2) (Genbank No. L42243) (6) Guanine Nucleotide Exchange Factor 1 (Genbank No. HG960-HT960) (7) Glucosamine-6-sulphatase precursor (Genbank No. Z12173) (8) MACH-beta-1 protein (Caspase 8)(Genbank No. X98176) (9) EST 15a11 Homo sapiens cDNA/gb=W25921/gi=1306044/ug=Hs.164036/len=723 (Genbank No. W25921) (10) Ndr protein kinase (Genbank No. Z35102) (11) 14-3-3 protein (Genbank No. U28964) (12) RbAp48 mRNA encoding retinoblastoma binding protein (Genbank No. X74262) (13) SNAP23B protein (Genbank No. Y09568) (14) Inhibitory protein for potassium-induced deficiency type 1 (SKD1 homolog) (Genbank No. AF038960) (15) Homo sapiens cDNA, 3′ end/clone=IMAGE-2509049, ETS wt31b09.x1 (Genbank No. A1955897) (16) Utrophin (Genbank No. X69086) (17) cdc2-related protein kinase (Genbank No. M80629) (18) Calmodulin type 1 (CALM1) (Genbank No. U12022) (19) Rb2/p130 protein (Genbank No. X74594) (20) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (21) GTP-binding protein RAB6 (Genbank No. M28212) (22) Clq/MBL/SPA receptor C1qR(p) (Genbank No. U94333) (23) Zinc finger/leucine zipper protein (AF10)(Genbank No. U13948) (24) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (25) Inositol polyphosphate 4-phosphatase (Genbank No. U26398) (26) Cytohesin binding protein HE (Genbank No. AF068836) (27) Cas like protein for enhancer of filamentation (HEF1) (Genbank No. L43821) (28) Rho GTPase-activated protein type 5 (p190-B) (Genbank No. U17032) (29) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (30) Syntaxin 16 (Genbank No. AF038897) (31) Cyclophilin-Related Protein (Genbank No. HG846-HT846) (32) Natural killer-tumor recognition sequence (Genbank No. L04288) (33) Integrin alpha 6B (CD49f) (Genbank No. S66213) (34) Homo sapiens clone 24629 mRNA sequence (Genbank No. AF052160) (35) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (36) mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585nt] (Genbank No. S79325) (37) Glucose transporter pseudogene (Genbank No. M55536) (38) Nuclear receptor intermediary activation factor 2 (TIF2) (Genbank No. X97674) (39) CRE-BP1 transcription factor (Genbank No. U16028) (40) Topoisomerase type II (Topo II) (Genbank No. M27504) (41) Nuclear respiratory factor-2 subunit alpha (Genbank No. U13044) (42) PAC clone DJ1185107 from 7q11.23-q21 RP5-1185I07 (Genbank No. AC004990) (43) Cyclin T2b (Genbank No. AF048732) (44) Zinc finger protein type C3H (MBLL) (Genbank No. AF061261) (45) MEK kinase (Mekk) (Genbank No. U29671) (46) Rod1 (Genbank No. AB023967) (47) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (48) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (49) pre-mRNA cleavage factor I subunit Im (Genbank No. AJ001810) (50) Homo sapiens cDNA, 3′ end/clone=IMAGE-2512364, EST wt65e11.x1 (Genbank No. A1961669) (51) Disintegrin-metalloprotease (Genbank No. Z48579) (52) ADP-ribosylation factor no.6 (ARF6) (Genbank No. AF047432) (53) Helicase like protein 2 containing DEAD/H box (DDX14) (Genbank No. U50553) (54) p300/CBP-associated factor (P/CAF) (Genbank No. U57317) (55) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (56) Cyclin G1 (Genbank No. X77794) (57) Guanine binding protein type q (Gaq) (Genbank No. U43083) (58) Trinucleotide repeat CGG-DNA binding protein p20-CGGBP (CGGBP) (Genbank No. AF094481) (59) Integrin alpha 4 subunit (CD49d) (Genbank No. L12002) (60) Chromosome 5q21-22, clone-A3-A (Genbank No. AB002450) (61) Unknown protein of uterine endometrium (Genbank No. X77723) (62) Transcription factor ISGF-3 (STAT91) (Genbank No. M97935) (63) Human PAC clone DJ525N14 from Xq23 RP3-525N14 (Genbank No. AC002086) (64) SH2 domain protein 1A isoform B (SH2D1A) (Genbank No. AF100539) (65) Killer cell lectin-like receptor NKG2F (Genbank No. AJ001683) (66) Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) (Genbank No. U13896) (67) Human SNF1-like protein kinase (Genbank No. U57452) (68) Human DNA for c-ets-1 proto-oncogene (Genbank No. X14798) (69) EAR-1r (Genbank No. D16815) (70) Guanine nucleotide regulatory protein (G alpha 13) (Genbank No. L22075) (71) Retinoblastoma susceptibility protein (RB1) (Genbank No. L49229) (72) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (73) EST 14e9 Homo sapiens cDNA (Genbank No. W25874) (74) MDM2-like p53-binding protein (MDMX) (Genbank No. AF007111) (75) Homo sapiens cDNA, 5′ end/clone=IMAGE-360208, EST ze27c09.r1 (Genbank No. AA013087) (76) Erythroblastosis virus oncogene homolog 1 (ets-1) (Genbank No. J04101) (77) HUMM9, Man9-mannosidase (Genbank No. X74837) (78) Kinesin/heavy chain SB (Genbank No. X65873) (79) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (80) Interferon regulatory factor-2 (IRF-2) (Genbank No. X15949) (81) Homo sapiens cDNA, 3′ end/clone=IMAGE-1722789, EST qd04h11.x1 (Genbank No. A1189226) (82) Chondroitin sulfate proteoglycan PG-M (bursicon) (Genbank No. D32039) (83) Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) (Genbank No. AL049962) (84) EST36b3 Homo sapiens cDNA (Genbank No. W27675) (85) Homo sapiens cDNA, 3′ end/clone=IMAGE-2489058, EST wr28g10.x1 (Genbank No. AW006742) (86) Homo sapiens cDNA, 3′ end/clone=IMAGE-815515, EST aa 38b10.s1 (Genbank No. AA457029) (87) c-myc proto-oncogene (MYCL2) (Genbank No. J03069) (88) Mature T cell proliferation factor c6.1B gene; MTCP1 gene (Genbank No. Z24459) (89) Homo sapiens mRNA for KIAA0797 protein (Genbank No. AB018340) (90) N-ras (Genbank No. X02751) (91) WD repeat protein HAN11 (Genbank No. U94747) (92) Homo sapiens mRNA for KIAA1048 protein (Genbank No. AB028971) (93) Homo sapiens mRNA for KIAA0454 protein (Genbank No. AB007923) (94) Cystine/glutamate transporter (Genbank No. AB026891) (95) Microsomal stress 70 protein ATPase core (stch) (Genbank No. U04735) (96) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (97) Homo sapiens cDNA, 5′ end/clone=IMAGE-2497327 (Genbank No AW003733) (98) Homo sapiens cDNA, 5′ end/clone=IMAGE-487691 (Genbank No. AA058762) (99) Monoamine oxidase B (MAOB) (Genbank No. M69177) (100) lipocortin-III (annexins A3) (Genbank No. M20560) (101) Homo sapiens chromosome 1 specific transcript KIAA0508 (Genbank No. AB007977) (102) Platelet-activating factor receptor (Genbank No. D10202) (103)EST DKFZp586A2224_s1 Homo sapiens cDNA (Genbank No. AL048308) (104) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (105) Gelsolin; macrophage capping protein; villin (Genbank No. M94345) (106) EST 31c9 Homo sapiens cDNA (Genbank No. W27466) (107) Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) (Genbank No. Y15909) (108) Insulin receptor precursor (Genbank No. X02160) (109) Heregulin type 1 (HRG alpha) (Genbank No. L11827) (110) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (111) Electron transfer flavoprotein beta subunit (Genbank No. X71129) (112) p160 (Genbank No. U88153) (113) Calciceurin dependently activated T cell nuclear factor (NF-Atc) (Genbank No. U08015) (114) Homo sapiens mRNA for KIAA0563 protein (Genbank No. AB011135) (115) Vscular smooth muscle alpha-actin (Genbank No. X13839) (116) Rad17-like protein (RAD17) (Genbank No. AF076838) (117) Homo sapiens cDNA, 3′ end/clone=IMAGE-2394055, EST wi54d04.x1 (Genbank No. AI762213) (118) Homo sapiens cDNA, 3 end/clone=IMAGE-979142, EST ni38e08.s1 (Genbank No. AA522537) (119) Human T54 protein (T54) (Genbank No. U66359) (120) Acyl-CoA dehydrogenase; SCAD gene (Genbank No. Z80345) (121) Phosphomevalonate kinase (Genbank No. L77213) (122) Drebrin E (Genbank No. D17530) (123) Receptor protein-tyrosine kinase EphA4 (HEK8) (Genbank No. L36645) (124) Tob family transducer ERBB2,2 (Genbank No. D64109) (125) Homo sapiens cDNA, 3 end/clone=IMAGE-1657913, ESTox31b09.s1 (Genbank No. A1039144) (126) Homogentisate 1,2-dioxygenase (Genbank No. AF000573) (127) MFH-proliferation sequence (MASL1) (Genbank No. AB016816) (128) Homo sapiens mRNA for KIAA0994 protein (Genbank No. AB023211) (129) Homo sapiens cDNA, 3 end/clone=IMAGE-826408, EST aa7le09.s1 (Genbank No. AA521060) (130) Neutrophil cytoplasmic factor type 4 (p4ophox) (Genbank No. X77094) (131) Mucin 5b (Genbank No. HG2689-HT2785) (132) Homo sapiens cDNA, 3 end/clone=IMAGE-965972, EST nh92c11.s1 (Genbank No. AA528252) (133) Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) (Genbank No. M14648) (134) Cluster Incl AL049435:Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220 (Genbank No. AL049435) (135) Homo sapiens (clone S164) mRNA, 3 end of cds/cds (Genbank No. L40392) (136) mRNA for KIAA1009 protein (Genbank No. AB023226) (137) mRNA for KIAA0716 protein (Genbank No. AB018259) (138) Vanin-like gene; vnn1 gene; VNN1 protein (Genbank No. AJ132099) (139) Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 (Genbank No. AC004893) (140) Homo sapiens mRNA for KIAA1050 protein (Genbank No. AB028973) (141) Human Chromosome 16 BAC clone CIT987SK-A-270G1 (Genbank No. AF001549) (142) Transcriptional factor TREB protein (Genbank No. X55544) (143) Homo sapiens mRNA for KIAA0548 protein (Genbank No. AB011120) (144) p300; transcriptional adaptor protein; E1A-binding protein (Genbank No. U01877) (145) Integrin alpha E precursor (CD103) (L25851) (146) Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1 (Genbank No. AI148772) (147) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 (Genbank No. AL109724) (148) Defensins alpha 3 (Genbank No. L12691) (149) Homo sapiens cDNA, 5′ end/clone=DKFZp564J2262-r1 (Genbank No. AL036554) (150) Elastase/medullasin (Genbank No. M34379) (151) Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) (Genbank No. AF002224) (152) Skeletal muscle 165 kD protein (Genbank No. X69089)
 10. The method according to claim 9, wherein expression levels of 2 to 50 kinds of genes derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia are utilized as an index for analyzing whether or not the expression level(s) of nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is statistically excluded from the range of expression level(s) in schizophrenic patients.
 11. The method according to claim 9, wherein expression levels of 2 to 20 kinds of genes derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia are utilized as an index for analyzing whether or not the expression level(s) of nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is statistically excluded from the range of the expression level(s) in schizophrenic patients.
 12. The method according to claim 9, wherein expression levels of 2 to 10 kinds of genes derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia are utilized as an index for analyzing whether or not the expression level(s) of nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is statistically excluded from the range of the expression level(s) in schizophrenic patients.
 13. The method according to claim 9, wherein expression level of 1 kind of gene derived from said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is utilized as an index for analyzing whether or not the expression level of nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is statistically excluded from the range of the expression level in schizophrenic patients.
 14. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, immobilizing at least one nucleic acid in said mononuclear cells onto a DNA micro-array or a DNA chip as a probe, the nucleic acid being selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia, determining the expression level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia all together using said DNA micro-array or said DNA chip immobilized with the nucleic acid, and comparing the determined level(s) with the determined level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or in schizophrenic patients to determine whether the alteration of said determined level(s) in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (152) with GenBank No. described in brackets. (1) Homo sapiens cDNA, 3′ end/clone=IMAGE-2329930, EST wd33c06.x1 (Genbank No. A1677689) (2) Bcl-Xl (Genbank No. Z23115) (3) ZNF37A mRNA for zinc finger (Genbank No. X69115) (4) HSCCG1 Human X chromsome mRNA for CCG1 protein inv. in cell proliferation (Genbank No. X07024) (5) Interferon receptor type 2 (IFNAR2) (Genbank No. L42243) (6) Guanine Nucleotide Exchange Factor 1 (Genbank No. HG960-HT960) (7) Glucosamine-6-sulphatase precursor (Genbank No. Z12173) (8) MACH-beta-1 protein (Caspase 8)(Genbank No. X98176) (9) EST 15a11 Homo sapiens cDNA/gb=W25921/gi=1306044/ug=Hs.164036/len=723 (Genbank No. W25921) (10) Ndr protein kinase (Genbank No. Z35102) (11) 14-3-3 protein (Genbank No. U28964) (12) RbAp48 mRNA encoding retinoblastoma binding protein (Genbank No. X74262) (13) SNAP23B protein (Genbank No. Y09568) (14) Inhibitory protein for potassium-induced deficiency type 1 (SKD1 homolog) (Genbank No. AF038960) (15) Homo sapiens cDNA, 3′ end/clone=IMAGE-2509049, ETS wt31b09.x1 (Genbank No. A1955897) (16) Utrophin (Genbank No. X69086) (17) cdc2-related protein kinase (Genbank No. M80629) (18) Calmodulin type 1 (CALM1) (Genbank No. U12022) (19) Rb2/p130 protein (Genbank No. X74594) (20) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (21) GTP-binding protein RAB6 (Genbank No. M28212) (22) Clq/MBL/SPA receptor C1qR(p) (Genbank No. U94333) (23) Zinc finger/leucine zipper protein (AF10)(Genbank No. U13948) (24) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (25) Inositol polyphosphate 4-phosphatase (Genbank No. U26398) (26) Cytohesin binding protein HE (Genbank No. AF068836) (27) Cas like protein for enhancer of filamentation (HEF1) (Genbank No. L43821) (28) Rho GTPase-activated protein type 5 (p190-B) (Genbank No. U17032) (29) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (30) Syntaxin 16 (Genbank No. AF038897) (31) Cyclophilin-Related Protein (Genbank No. HG846-HT846) (32) Natural killer-tumor recognition sequence (Genbank No. L04288) (33) Integrin alpha 6B (CD49f) (Genbank No. S66213) (34) Homo sapiens clone 24629 mRNA sequence (Genbank No. AF052160) (35) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (36) mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585nt] (Genbank No. S79325) (37) Glucose transporter pseudogene (Genbank No. M55536) (38) Nuclear receptor intermediary activation factor 2 (TIF2) (Genbank No. X97674) (39) CRE-BP1 transcription factor (Genbank No. U16028) (40) Topoisomerase type II (Topo II) (Genbank No. M27504) (41) Nuclear respiratory factor-2 subunit alpha (Genbank No. U13044) (42) PAC clone DJ1185107 from 7q11.23-q21 RP5-1185107 (Genbank No. AC004990) (43) Cyclin T2b (Genbank No. AF048732) (44) Zinc finger protein type C3H (MBLL) (Genbank No. AF061261) (45) MEK kinase (Mekk) (Genbank No. U29671) (46) Rod1 (Genbank No. AB023967) (47) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (48) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (49) pre-mRNA cleavage factor I subunit Im (Genbank No. AJ001810) (50) Homo sapiens cDNA, 3′ end/clone=IMAGE-2512364, EST wt65e11.x1 (Genbank No. AI961669) (51) Disintegrin-metalloprotease (Genbank No. Z48579) (52) ADP-ribosylation factor no.6 (ARF6) (Genbank No. AF047432) (53) Helicase like protein 2 containing DEAD/H box (DDX14) (Genbank No. U50553) (54) p300/CBP-associated factor (P/CAF) (Genbank No. U57317) (55) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (56) Cyclin G1 (Genbank No. X77794) (57) Guanine binding protein type q (Gaq) (Genbank No. U43083) (58) Trinucleotide repeat CGG-DNA binding protein p20-CGGBP (CGGBP) (Genbank No. AF094481) (59) Integrin alpha 4 subunit (CD49d) (Genbank No. L12002) (60) Chromosome 5q21-22, clone-A3-A (Genbank No. AB002450) (61) Unknown protein of uterine endometrium (Genbank No. X77723) (62) Transcription factor ISGF-3 (STAT91) (Genbank No. M97935) (63) Human PAC clone DJ525N14 from Xq23 RP3-525N14 (Genbank No. AC002086) (64) SH2 domain protein 1A isoform B (SH2D1A) (Genbank No. AF100539) (65) Killer cell lectin-like receptor NKG2F (Genbank No. AJ001683) (66) Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) (Genbank No. U13896) (67) Human SNF1-like protein kinase (Genbank No. U57452) (68) Human DNA for c-ets-1 proto-oncogene (Genbank No. X14798) (69) EAR-1r (Genbank No. D16815) (70) Guanine nucleotide regulatory protein (G alpha 13) (Genbank No. L22075) (71) Retinoblastoma susceptibility protein (RB1) (Genbank No. L49229) (72) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (73) EST 14e9 Homo sapiens cDNA (Genbank No. W25874) (74) MDM2-like p53-binding protein (MDMX) (Genbank No. AF007111) (75) Homo sapiens cDNA, 5′ end/clone=IMAGE-360208, EST ze27c09.r1 (Genbank No. AA013087) (76) Erythroblastosis virus oncogene homolog 1 (ets-1) (Genbank No. J04101) (77) HUMM9, Man9-mannosidase (Genbank No. X74837) (78) Kinesin/heavy chain 5B (Genbank No. X65873) (79) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (80) Interferon regulatory factor-2 (IRF-2) (Genbank No. X15949) (81) Homo sapiens cDNA, 3′ end/clone=IMAGE-1722789, EST qd04h11.x1 (Genbank No. AI189226) (82) Chondroitin sulfate proteoglycan PG-M (bursicon) (Genbank No. D32039) (83) Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) (Genbank No. AL049962) (84) EST36b3 Homo sapiens cDNA (Genbank No. W27675) (85) Homo sapiens cDNA, 3′ end/clone=IMAGE-2489058, EST wr28g10.x1 (Genbank No. AW006742) (86) Homo sapiens cDNA, 3′ end/clone=IMAGE-815515, EST aa 38b10.s1 (Genbank No. AA457029) (87) c-myc proto-oncogene (MYCL2) (Genbank No. J03069) (88) Mature T cell proliferation factor c6.1B gene; MTCP1 gene (Genbank No. Z24459) (89) Homo sapiens mRNA for KIAA0797 protein (Genbank No. AB018340) (90) N-ras (Genbank No. X02751) (91) WD repeat protein HAN11 (Genbank No. U94747) (92) Homo sapiens mRNA for KIAA1048 protein (Genbank No. AB028971) (93) Homo sapiens mRNA for KIAA0454 protein (Genbank No. AB007923) (94) Cystine/glutamate transporter (Genbank No. AB026891) (95) Microsomal stress 70 protein ATPase core (stch) (Genbank No. U04735) (96) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (97) Homo sapiens cDNA, 5′ end/clone=IMAGE-2497327 (Genbank No AW003733) (98) Homo sapiens cDNA, 5′ end/clone=IMAGE-487691 (Genbank No. AA058762) (99) Monoamine oxidase B (MAOB) (Genbank No. M69177) (100) lipocortin-III (annexins A3) (Genbank No. M20560) (101) Homo sapiens chromosome 1 specific transcript KIAA0508 (Genbank No. AB007977) (102) Platelet-activating factor receptor (Genbank No. D10202) (103)EST DKFZp586A2224_s1 Homo sapiens cDNA (Genbank No. AL048308) (104) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (105) Gelsolin; macrophage capping protein; villin (Genbank No. M94345) (106) EST 31c9 Homo sapiens cDNA (Genbank No. W27466) (107) Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) (Genbank No. Y15909) (108) Insulin receptor precursor (Genbank No. X02160) (109) Heregulin type 1 (HRG alpha) (Genbank No. L41827) (110) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (111) Electron transfer flavoprotein beta subunit (Genbank No. X71129) (112) p160 (Genbank No. U88153) (113) Calciceurin dependently activated T cell nuclear factor (NF-Atc) (Genbank No. U08015) (114) Homo sapiens mRNA for KIAA0563 protein (Genbank No. AB011135) (115) Vscular smooth muscle alpha-actin (Genbank No. X13839) (116) Rad17-like protein (RAD17) (Genbank No. AF076838) (117) Homo sapiens cDNA, 3′ end/clone=IMAGE-2394055, EST wi54d04.x1 (Genbank No. A1762213) (118) Homo sapiens cDNA, 3 end/clone=IMAGE-979142, EST ni38e08.s1 (Genbank No. AA522537) (119) Human T54 protein (T54) (Genbank No. U66359) (120) Acyl-CoA dehydrogenase; SCAD gene (Genbank No. Z80345) (121) Phosphomevalonate kinase (Genbank No. L77213) (122) Drebrin E (Genbank No. D17530) (123) Receptor protein-tyrosine kinase EphA4 (HEK8) (Genbank No. L36645) (124) Tob family transducer ERBB2,2 (Genbank No. D64109) (125) Homo sapiens cDNA, 3 end/clone=IMAGE-1657913, ESTox31b09.s1 (Genbank No. A1039144) (126) Homogentisate 1,2-dioxygenase (Genbank No. AF000573) (127) MFH-proliferation sequence (MASL1) (Genbank No. AB016816) (128) Homo sapiens mRNA for KIAA0994 protein (Genbank No. AB023211) (129) Homo sapiens cDNA, 3 end/clone=IMAGE-826408, EST aa71e09.s1 (Genbank No. AA521060) (130) Neutrophil cytoplasmic factor type 4 (p40phox) (Genbank No. X77094) (131) Mucin 5b (Genbank No. HG2689-HT2785) (132) Homo sapiens cDNA, 3 end/clone=IMAGE-965972, EST nh92c11.s1 (Genbank No. AA528252) (133) Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) (Genbank No. M14648) (134) Cluster Incl AL049435:Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220 (Genbank No. AL049435) (135) Homo sapiens (clone S164) mRNA, 3 end of cds/cds (Genbank No. L40392) (136) mRNA for KIAA1009 protein (Genbank No. AB023226) (137) mRNA for KIAA0716 protein (Genbank No. AB018259) (138) Vanin-like gene; vnn1 gene; VNN1 protein (Genbank No. AJ132099) (139) Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 (Genbank No. AC004893) (140) Homo sapiens mRNA for KIAA1050 protein (Genbank No. AB028973) (141) Human Chromosome 16 BAC clone CIT987SK-A-270G1 (Genbank No. AF001549) (142) Transcriptional factor TREB protein (Genbank No. X55544) (143) Homo sapiens mRNA for KIAA0548 protein (Genbank No. AB011120) (144) p300; transcriptional adaptor protein; E1A-binding protein (Genbank No. U01877) (145) Integrin alpha E precursor (CD103) (L25851) (146) Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1 (Genbank No. A1148772) (147) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 (Genbank No. AL109724) (148) Defensins alpha 3 (Genbank No. L12691) (149) Homo sapiens cDNA, 5′ end/clone=DKFZp564J2262-r1 (Genbank No. AL036554) (150) Elastase/medullasin (Genbank No. M34379) (151) Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) (Genbank No. AF002224) (152) Skeletal muscle 165 kD protein (Genbank No. X69089)
 15. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, measuring the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and comparing multiplicative values of the probabilities obtained from the statistical distributions or deviations of the quantified value(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in said test subject with the multiplicative values of the probabilities in healthy subjects or in schizophrenic patients to determine whether the alteration of the content of the gene in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (152) with GenBank No. described in brackets. (1) Homo sapiens cDNA, 3′ end/clone=IMAGE-2329930, EST wd33c06.x1 (Genbank No. A1677689) (2) Bcl-Xl (Genbank No. Z23115) (3) ZNF37A mRNA for zinc finger (Genbank No. X69115) (4) HSCCG1 Human X chromsome mRNA for CCG1 protein inv. in cell proliferation (Genbank No. X07024) (5) Interferon receptor type 2 (IFNAR2) (Genbank No. L42243) (6) Guanine Nucleotide Exchange Factor 1 (Genbank No. HG960-HT960) (7) Glucosamine-6-sulphatase precursor (Genbank No. Z12173) (8) MACH-beta-1 protein (Caspase 8)(Genbank No. X98176) (9) EST 15a11 Homo sapiens cDNA/gb=W25921/gi=1306044/ug=Hs.164036/len=723 (Genbank No. W25921) (10) Ndr protein kinase (Genbank No. Z35102) (11) 14-3-3 protein (Genbank No. U28964) (12) RbAp48 mRNA encoding retinoblastoma binding protein (Genbank No. X74262) (13) SNAP23B protein (Genbank No. Y09568) (14) Inhibitory protein for potassium-induced deficiency type 1 (SKD1 homolog) (Genbank No. AF038960) (15) Homo sapiens cDNA, 3′ end/clone=IMAGE-2509049, ETS wt31b09.x1 (Genbank No. A1955897) (16) Utrophin (Genbank No. X69086) (17) cdc2-related protein kinase (Genbank No. M80629) (18) Calmodulin type 1 (CALM1) (Genbank No. U12022) (19) Rb2/p130 protein (Genbank No. X74594) (20) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (21) GTP-binding protein RAB6 (Genbank No. M28212) (22) Clq/MBL/SPA receptor C1qR(p) (Genbank No. U94333) (23) Zinc finger/leucine zipper protein (AF10)(Genbank No. U13948) (24) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (25) Inositol polyphosphate 4-phosphatase (Genbank No. U26398) (26) Cytobesin binding protein HE (Genbank No. AF068836) (27) Cas like protein for enhancer of filamentation (HEF1) (Genbank No. L43821) (28) Rho GTPase-activated protein type 5 (p190-B) (Genbank No. U17032) (29) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (30) Syntaxin 16 (Genbank No. AF038897) (31) Cyclophilin-Related Protein (Genbank No. HG846-HT846) (32) Natural killer-tumor recognition sequence (Genbank No. L04288) (33) Integrin alpha 6B (CD49f) (Genbank No. S66213) (34) Homo sapiens clone 24629 mRNA sequence (Genbank No. AF052160) (35) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (36) mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585nt] (Genbank No. S79325) (37) Glucose transporter pseudogene (Genbank No. M55536) (38) Nuclear receptor intermediary activation factor 2 (TIF2) (Genbank No. X97674) (39) CRE-BP1 transcription factor (Genbank No. U16028) (40) Topoisomerase type II (Topo II) (Genbank No. M27504) (41) Nuclear respiratory factor-2 subunit alpha (Genbank No. U13044) (42) PAC clone DJ1185107 from 7q11.23-q21 RP5-1185107 (Genbank No. AC004990) (43) Cyclin T2b (Genbank No. AF048732) (44) Zinc finger protein type C3H (MBLL) (Genbank No. AF061261) (45) MEK kinase (Mekk) (Genbank No. U29671) (46) Rod1 (Genbank No. AB023967) (47) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (48) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (49) pre-mRNA cleavage factor I subunit Im (Genbank No. AJ001810) (50) Homo sapiens cDNA, 3′ end/clone=IMAGE-2512364, EST wt65e11.x1 (Genbank No. AI961669) (51) Disintegrin-metalloprotease (Genbank No. Z48579) (52) ADP-ribosylation factor no.6 (ARF6) (Genbank No. AF047432) (53) Helicase like protein 2 containing DEAD/H box (DDX14) (Genbank No. U50553) (54) p300/CBP-associated factor (P/CAF) (Genbank No. U57317) (55) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (56) Cyclin G1 (Genbank No. X77794) (57) Guanine binding protein type q (Gaq) (Genbank No. U43083) (58) Trinucleotide repeat CGG-DNA binding protein p20-CGGBP (CGGBP) (Genbank No. AF094481) (59) Integrin alpha 4 subunit (CD49d) (Genbank No. L12002) (60) Chromosome 5q21-22, clone-A3-A (Genbank No. AB002450) (61) Unknown protein of uterine endometrium (Genbank No. X77723) (62) Transcription factor ISGF-3 (STAT91) (Genbank No. M97935) (63) Human PAC clone DJ525N14 from Xq23 RP3-525N14 (Genbank No. AC002086) (64) SH2 domain protein 1A isoform B (SH2D1A) (Genbank No. AF100539) (65) Killer cell lectin-like receptor NKG2F (Genbank No. AJ001683) (66) Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) (Genbank No. U13896) (67) Human SNF1-like protein kinase (Genbank No. U57452) (68) Human DNA for c-ets-1 proto-oncogene (Genbank No. X14798) (69) EAR-1r (Genbank No. D16815) (70) Guanine nucleotide regulatory protein (G alpha 13) (Genbank No. L22075) (71) Retinoblastoma susceptibility protein (RB1) (Genbank No. L49229) (72) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (73) EST 14e9 Homo sapiens cDNA (Genbank No. W25874) (74) MDM2-like p53-binding protein (MDMX) (Genbank No. AF007111) (75) Homo sapiens cDNA, 5′ end/clone=IMAGE-360208, EST ze27c09.r1 l (Genbank No. AA013087) (76) Erythroblastosis virus oncogene homolog 1 (ets-1) (Genbank No. J04101) (77) HUMM9, Man9-mannosidase (Genbank No. X74837) (78) Kinesin/heavy chain 5B (Genbank No. X65873) (79) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (80) Interferon regulatory factor-2 (IRF-2) (Genbank No. X15949) (81) Homo sapiens cDNA, 3′ end/clone=IMAGE-1722789, EST qd04h11.x1 (Genbank No. AI189226) (82) Chondroitin sulfate proteoglycan PG-M (bursicon) (Genbank No. D32039) (83) Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) (Genbank No. AL049962) (84) EST36b3 Homo sapiens cDNA (Genbank No. W27675) (85) Homo sapiens cDNA, 3′ end/clone=IMAGE-2489058, EST wr28g10.x1 (Genbank No. AW006742) (86) Homo sapiens cDNA, 3′ end/clone=IMAGE-815515, EST aa 38b10.s1 (Genbank No. AA457029) (87) c-myc proto-oncogene (MYCL2) (Genbank No. J03069) (88) Mature T cell proliferation factor c6.1B gene; MTCP1 gene (Genbank No. Z24459) (89) Homo sapiens mRNA for KIAA0797 protein (Genbank No. AB018340) (90) N-ras (Genbank No. X02751) (91) WD repeat protein HAN11 (Genbank No. U94747) (92) Homo sapiens mRNA for KIAA1048 protein (Genbank No. AB028971) (93) Homo sapiens mRNA for KIAA0454 protein (Genbank No. AB007923) (94) Cystine/glutamate transporter (Genbank No. AB026891) (95) Microsomal stress 70 protein ATPase core (stch) (Genbank No. U04735) (96) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (97) Homo sapiens cDNA, 5′ end/clone=IMAGE-2497327 (Genbank No AW003733) (98) Homo sapiens cDNA, 5′ end/clone=IMAGE-487691 (Genbank No. AA058762) (99) Monoamine oxidase B (MAOB) (Genbank No. M69177) (100) lipocortin-III (annexins A3) (Genbank No. M20560) (101) Homo sapiens chromosome 1 specific transcript KIAA0508 (Genbank No. AB007977) (102) Platelet-activating factor receptor (Genbank No. D10202) (103) EST DKFZp586A2224_s1 Homo sapiens cDNA (Genbank No. AL048308) (104) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (105) Gelsolin; macrophage capping protein; villin (Genbank No. M94345) (106) EST 31c9 Homo sapiens cDNA (Genbank No. W27466) (107) Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) (Genbank No. Y15909) (108) Insulin receptor precursor (Genbank No. X02160) (109) Heregulin type 1 (HRG alpha) (Genbank No. L41827) (110) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (111) Electron transfer flavoprotein beta subunit (Genbank No. X71129) (112) p160 (Genbank No. U88153) (113) Calciceurin dependently activated T cell nuclear factor (NF-Atc) (Genbank No. U08015) (114) Homo sapiens mRNA for KIAA0563 protein (Genbank No. AB011135) (115) Vscular smooth muscle alpha-actin (Genbank No. X13839) (116) Rad17-like protein (RAD17) (Genbank No. AF076838) (117) Homo sapiens cDNA, 3′ end/clone=IMAGE-2394055, EST wi54d04.x1 (Genbank No. A1762213) (118) Homo sapiens cDNA, 3 end/clone=IMAGE-979142, EST ni38e08.s1 (Genbank No. AA522537) (119) Human T54 protein (T54) (Genbank No. U66359) (120) Acyl-CoA dehydrogenase; SCAD gene (Genbank No. Z80345) (121) Phosphomevalonate kinase (Genbank No. L77213) (122) Drebrin E (Genbank No. D17530) (123) Receptor protein-tyrosine kinase EphA4 (HEK8) (Genbank No. L36645) (124) Tob family transducer ERBB2,2 (Genbank No. D64109) (125) Homo sapiens cDNA, 3 end/clone=IMAGE-1657913, ESTox31b09.s1 (Genbank No. A1039144) (126) Homogentisate 1,2-dioxygenase (Genbank No. AF000573) (127) MFH-proliferation sequence (MASL1) (Genbank No. AB016816) (128) Homo sapiens mRNA for KIAA0994 protein (Genbank No. AB023211) (129) Homo sapiens cDNA, 3 end/clone=IMAGE-826408, EST aa71e09.s1 (Genbank No. AA521060) (130) Neutrophil cytoplasmic factor type 4 (p40phox) (Genbank No. X77094) (131) Mucin 5b (Genbank No. HG2689-HT2785) (132) Homo sapiens cDNA, 3 end/clone=IMAGE-965972, EST nh92c11.s1 (Genbank No. AA528252) (133) Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) (Genbank No. M14648) (134) Cluster Incl AL049435:Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220 (Genbank No. AL049435) (135) Homo sapiens (clone S164) mRNA, 3 end of cds/cds (Genbank No. LA0392) (136) mRNA for KIAA1009 protein (Genbank No. AB023226) (137) mRNA for KIAA0716 protein (Genbank No. AB018259) (138) Vanin-like gene; vnn1 gene; VNN1 protein (Genbank No. AJ132099) (139) Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 (Genbank No. AC004893) (140) Homo sapiens mRNA for KIAA1050 protein (Genbank No. AB028973) (141) Human Chromosome 16 BAC clone CIT987SK-A-270G1 (Genbank No. AF001549) (142) Transcriptional factor TREB protein (Genbank No. X55544) (143) Homo sapiens mRNA for KIAA0548 protein (Genbank No. AB011120) (144) p300; transcriptional adaptor protein; E1A-binding protein (Genbank No. U01877) (145) Integrin alpha E precursor (CD103) (L25851) (146) Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1 (Genbank No. AI148772) (147) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 (Genbank No. AL109724) (148) Defensins alpha 3 (Genbank No. L12691) (149) Homo sapiens cDNA, 5′ end/clone=DKFZp564J2262-r1 (Genbank No. AL036554) (150) Elastase/medullasin (Genbank No. M34379) (151) Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) (Genbank No. AF002224) (152) Skeletal muscle 165 kD protein (Genbank No. X69089)
 16. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, determining the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and comparing the discriminant value(s) obtained by linear weighted addition of the quantified value(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia with the discriminant value(s) in healthy subjects or schizophrenic patients obtained by linear weighted addition to determine whether the alteration of the discriminant value(s) of the gene in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (152) with GenBank No. described in brackets. (1) Homo sapiens cDNA, 3′ end/clone=IMAGE-2329930, EST wd33c06.x1 (Genbank No. AI677689) (2) Bcl-Xl (Genbank No. Z23115) (3) ZNF37A mRNA for zinc finger (Genbank No. X69115) (4) HSCCG1 Human X chromsome mRNA for CCG1 protein inv. in cell proliferation (Genbank No. X07024) (5) Interferon receptor type 2 (IFNAR2) (Genbank No. L42243) (6) Guanine Nucleotide Exchange Factor 1 (Genbank No. HG960-HT960) (7) Glucosamine-6-sulphatase precursor (Genbank No. Z12173) (8) MACH-beta-1 protein (Caspase 8)(Genbank No. X98176) (9) EST 15a11 Homo sapiens cDNA/gb=W25921/gi=1306044/ug=Hs.164036/len=723 (Genbank No. W25921) (10) Ndr protein kinase (Genbank No. Z35102) (11) 14-3-3 protein (Genbank No. U28964) (12) RbAp48 mRNA encoding retinoblastoma binding protein (Genbank No. X74262) (13) SNAP23B protein (Genbank No. Y09568) (14) Inhibitory protein for potassium-induced deficiency type 1 (SKD1 homolog) (Genbank No. AF038960) (15) Homo sapiens cDNA, 3′ end/clone=IMAGE-2509049, ETS wt31b09.x1 (Genbank No. A1955897) (16) Utrophin (Genbank No. X69086) (17) cdc2-related protein kinase (Genbank No. M80629) (18) Calmodulin type 1 (CALM1) (Genbank No. U12022) (19) Rb2/p130 protein (Genbank No. X74594) (20) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (21) GTP-binding protein RAB6 (Genbank No. M28212) (22) Clq/MBL/SPA receptor C1qR(p) (Genbank No. U94333) (23) Zinc finger/leucine zipper protein (AF10)(Genbank No. U13948) (24) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (25) Inositol polyphosphate 4-phosphatase (Genbank No. U26398) (26) Cytohesin binding protein HE (Genbank No. AF068836) (27) Cas like protein for enhancer of filamentation (HEF1) (Genbank No. L43821) (28) Rho GTPase-activated protein type 5 (p190-B) (Genbank No. U17032) (29) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (30) Syntaxin 16 (Genbank No. AF038897) (31) Cyclophilin-Related Protein (Genbank No. HG846-HT846) (32) Natural killer-tumor recognition sequence (Genbank No. L04288) (33) Integrin alpha 6B (CD49f) (Genbank No. S66213) (34) Homo sapiens clone 24629 mRNA sequence (Genbank No. AF052160) (35) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (36) mRNA for SYT.SSX1 translocational target region of human synovial inducible sarcomas [Partial Mutant, 3′ genes, 585nt] (Genbank No. S79325) (37) Glucose transporter pseudogene (Genbank No. M55536) (38) Nuclear receptor intermediary activation factor 2 (TIF2) (Genbank No. X97674) (39) CRE-BP1 transcription factor (Genbank No. U16028) (40) Topoisomerase type II (Topo II) (Genbank No. M27504) (41) Nuclear respiratory factor-2 subunit alpha (Genbank No. U13044) (42) PAC clone DJ1185I07 from 7q11.23-q21 RP5-1185I07 (Genbank No. AC004990) (43) Cyclin T2b (Genbank No. AF048732) (44) Zinc finger protein type C3H (MBLL) (Genbank No. AF061261) (45) MEK kinase (Mekk) (Genbank No. U29671) (46) Rod1 (Genbank No. AB023967) (47) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (48) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (49) pre-mRNA cleavage factor I subunit Im (Genbank No. AJ001810) (50) Homo sapiens cDNA, 3′ end/clone=IMAGE-2512364, EST wt65e11.x1 (Genbank No. A1961669) (51) Disintegrin-metalloprotease (Genbank No. Z48579) (52) ADP-ribosylation factor no.6 (ARF6) (Genbank No. AF047432) (53) Helicase like protein 2 containing DEAD/H box (DDX14) (Genbank No. U50553) (54) p300/CBP-associated factor (P/CAF) (Genbank No. U57317) (55) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (56) Cyclin GI (Genbank No. X77794) (57) Guanine binding protein type q (Gaq) (Genbank No. U43083) (58) Trinucleotide repeat CGG-DNA binding protein p20-CGGBP (CGGBP) (Genbank No. AF094481) (59) Integrin alpha 4 subunit (CD49d) (Genbank No. L12002) (60) Chromosome 5q21-22, clone-A3-A (Genbank No. AB002450) (61) Unknown protein of uterine endometrium (Genbank No. X77723) (62) Transcription factor ISGF-3 (STAT91) (Genbank No. M97935) (63) Human PAC clone DJ525N14 from Xq23 RP3-525N14 (Genbank No. AC002086) (64) SH2 domain protein 1A isoform B (SH2D1A) (Genbank No. AF100539) (65) Killer cell lectin-like receptor NKG2F (Genbank No. AJ001683) (66) Human homolog of Drosophila discs gene, isoform 2 (hdlg-2) (Genbank No. U13896) (67) Human SNF1-like protein kinase (Genbank No. U57452) (68) Human DNA for c-ets-1 proto-oncogene (Genbank No. X14798) (69) EAR-1r (Genbank No. D16815) (70) Guanine nucleotide regulatory protein (G alpha 13) (Genbank No. L22075) (71) Retinoblastoma susceptibility protein (RB1) (Genbank No. L49229) (72) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (73) EST 14e9 Homo sapiens cDNA (Genbank No. W25874) (74) MDM2-like p53-binding protein (MDMX) (Genbank No. AF007111) (75) Homo sapiens cDNA, 5′ end/clone=IMAGE-360208, EST ze27c09.r1 (Genbank No. AA013087) (76) Erythroblastosis virus oncogene homolog 1 (ets-1) (Genbank No. J04101) (77) HUMM9, Man9-mannosidase (Genbank No. X74837) (78) Kinesin/heavy chain 5B (Genbank No. X65873) (79) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (80) Interferon regulatory factor-2 (IRF-2) (Genbank No. X15949) (81) Homo sapiens cDNA, 3′ end/clone=IMAGE-1722789, EST qd04h11.x1 (Genbank No. A1189226) (82) Chondroitin sulfate proteoglycan PG-M (bursicon) (Genbank No. D32039) (83) Homo sapiens mRNA; cDNA DKFZp564P0823 (from clone DKFZp564P0823) (Genbank No. AL049962) (84) EST36b3 Homo sapiens cDNA (Genbank No. W27675) (85) Homo sapiens cDNA, 3′ end/clone=IMAGE-2489058, EST wr28g10.x1 (Genbank No. AW006742) (86) Homo sapiens cDNA, 3′ end/clone=IMAGE-815515, EST aa 38b10.s1 (Genbank No. AA457029) (87) c-myc proto-oncogene (MYCL2) (Genbank No. J03069) (88) Mature T cell proliferation factor c6.1B gene; MTCP1 gene (Genbank No. Z24459) (89) Homo sapiens mRNA for KIAA0797 protein (Genbank No. AB018340) (90) N-ras (Genbank No. X02751) (91) WD repeat protein HAN11 (Genbank No. U94747) (92) Homo sapiens mRNA for KIAA1048 protein (Genbank No. AB028971) (93) Homo sapiens mRNA for KIAA0454 protein (Genbank No. AB007923) (94) Cystine/glutamate transporter (Genbank No. AB026891) (95) Microsomal stress 70 protein ATPase core (stch) (Genbank No. U04735) (96) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (97) Homo sapiens cDNA, 5′ end/clone=IMAGE-2497327 (Genbank No AW003733) (98) Homo sapiens cDNA, 5′ end/clone=IMAGE-487691 (Genbank No. AA058762) (99) Monoamine oxidase B (MAOB) (Genbank No. M69177) (100) lipocortin-III (annexins A3) (Genbank No. M20560) (101) Homo sapiens chromosome 1 specific transcript KIAA0508 (Genbank No. AB007977) (102) Platelet-activating factor receptor (Genbank No. D10202) (103) EST DKFZp586A2224_s1 Homo sapiens cDNA (Genbank No. AL048308) (104) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (105) Gelsolin; macrophage capping protein; villin (Genbank No. M94345) (106) EST 31c9 Homo sapiens cDNA (Genbank No. W27466) (107) Diaphanous type 2 isoform 12C protein, dia-156 protein (DIA-156) (Genbank No. Y15909) (108) Insulin receptor precursor (Genbank No. X02160) (109) Heregulin type 1 (HRG alpha) (Genbank No. L41827) (110) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (111) Electron transfer flavoprotein beta subunit (Genbank No. X71129) (112) p160 (Genbank No. U88153) (113) Calciceurin dependently activated T cell nuclear factor (NF-Atc) (Genbank No. U08015) (114) Homo sapiens mRNA for KIAA0563 protein (Genbank No. AB011135) (115) Vscular smooth muscle alpha-actin (Genbank No. X13839) (116) Rad17-like protein (RAD17) (Genbank No. AF076838) (117) Homo sapiens cDNA, 3′ end/clone=IMAGE-2394055, EST wi54d04.x1 (Genbank No. AI762213) (118) Homo sapiens cDNA, 3 end/clone=IMAGE-979142, EST ni38e08.s1 (Genbank No. AA522537) (119) Human T54 protein (T54) (Genbank No. U66359) (120) Acyl-CoA dehydrogenase; SCAD gene (Genbank No. Z80345) (121) Phosphomevalonate kinase (Genbank No. L77213) (122) Drebrin E (Genbank No. D17530) (123) Receptor protein-tyrosine kinase EphA4 (HEK8) (Genbank No. L36645) (124) Tob family transducer ERBB2,2 (Genbank No. D64109) (125) Homo sapiens cDNA, 3 end/clone=IMAGE-1657913, ESTox31b09.s1 (Genbank No. A1039144) (126) Homogentisate 1,2-dioxygenase (Genbank No. AF000573) (127) MFH-proliferation sequence (MASL1) (Genbank No. AB016816) (128) Homo sapiens mRNA for KIAA0994 protein (Genbank No. AB023211) (129) Homo sapiens cDNA, 3 end/clone=IMAGE-826408, EST aa71e09.s1 (Genbank No. AA521060) (130) Neutrophil cytoplasmic factor type 4 (p40phox) (Genbank No. X77094) (131) Mucin 5b (Genbank No. HG2689-HT2785) (132) Homo sapiens cDNA, 3 end/clone=IMAGE-965972, EST nh92c11.s1 (Genbank No. AA528252) (133) Cell adhesion protein (vitronectin) receptor alpha subunit (CD51) (Genbank No. M14648) (134) Cluster Incl AL049435:Homo sapiens mRNA; cDNA DKFZp586B0220 (from clone DKFZp586B0220 (Genbank No. AL049435) (135) Homo sapiens (clone S164) mRNA, 3 end of cds/cds (Genbank No. L40392) (136) mRNA for KIAA1009 protein (Genbank No. AB023226) (137) mRNA for KIAA0716 protein (Genbank No. AB018259) (138) Vanin-like gene; vnn1 gene; VNN1 protein (Genbank No. AJ132099) (139) Homo sapiens PAC clone DJ0808A01 from 7q21.1-q31.1 (Genbank No. AC004893) (140) Homo sapiens mRNA for KIAA1050 protein (Genbank No. AB028973) (141) Human Chromosome 16 BAC clone CIT987SK-A-270G1 (Genbank No. AF001549) (142) Transcriptional factor TREB protein (Genbank No. X55544) (143) Homo sapiens mRNA for KIAA0548 protein (Genbank No. AB011120) (144) p300; transcriptional adaptor protein; E1A-binding protein (Genbank No. U01877) (145) Integrin alpha E precursor (CD103) (L25851) (146) Homo sapiens cDNA, 3 end/clone=IMAGE-1714897 EST qc69h01.x1 (Genbank No. A1148772) (147) Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 417629 (Genbank No. AL109724) (148) Defensins alpha 3 (Genbank No. L12691) (149) Homo sapiens cDNA, 5′ end/clone=DKFZp564J2262-r1 (Genbank No. AL036554) (150) Elastase/medullasin (Genbank No. M34379) (151) Angelman Syndrome Gene, E6-AP ubiquitin protein ligase 3A (UBE3A) (Genbank No. AF002224) (152) Skeletal muscle 165 kD protein (Genbank No. X69089)
 17. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cells in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, determining the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, and comparing the discriminant value(s) obtained by linear weighted addition of the quantified value(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia with the discriminant value(s) in healthy subjects or schizophrenic patients obtained by linear weighted addition to determine whether the alteration of the discriminant value(s) of the gene in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) encoding enzyme(s) catalyzing transfer of phosphate group(s) (kinase or phosphatase) and defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (16) with GenBank No described in brackets. (1) Ndr protein kinase (Genbank No. Z35102) (2) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (3) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (4) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (5) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (6) MEK kinase (Mekk) (Genbank No. U29671) (7) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (8) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (9) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (10) Human SNF1-like protein kinase (Genbank No. U57452) (11) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (12) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (13) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (14) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (15) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (16) Phosphomevalonate kinase (Genbank No. L77213)
 18. A method to discriminate a subject suffering from schizophrenia from a subject suffering from other psychiatric diseases, the method comprising the steps of; obtaining mononuclear cells in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, determining the content of at least one nucleic acid selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia in said mononuclear cells, comparing the discriminant value(s) obtained by linear weighted addition of the quantified value(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia with the discriminant value(s) in healthy subjects or schizophrenic patients obtained by linear weighted addition to determine whether the alteration of the discriminant value(s) of the gene in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) encoding enzyme(s) catalyzing transfer of phosphate group(s) (kinase or phosphatase) and defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (16) with GenBank No described in brackets. (1) Ndr protein kinase (Genbank No. Z35102) (2) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (3) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (4) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (5) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (6) MEK kinase (Mekk) (Genbank No. U29671) (7) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (8) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (9) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (10) Human SNF1-like protein kinase (Genbank No. U57452) (11) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (12) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (13) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (14) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (15) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (16) Phosphomevalonate kinase (Genbank No. L77213)
 19. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cell in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, immobilizing at least one nucleic acid in said mononuclear cells onto a DNA micro-array or a DNA chip as a probe, the nucleic acid being selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia, determining the expression level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia all together using said DNA micro-array or said DNA chip immobilized with the nucleic acid(s), and comparing the determined level(s) with the determined level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or in schizophrenic patients to determine whether the alteration of said determined level(s) in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) encoding enzyme(s) catalyzing transfer of phosphate group(s) (kinase or phosphatase) and defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (16) with GenBank No described in brackets. (1) Ndr protein kinase (Genbank No. Z35102) (2) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (3) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (4) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (5) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (6) MEK kinase (Mekk) (Genbank No. U29671) (7) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (8) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (9) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (10) Human SNF1-like protein kinase (Genbank No. U57452) (11) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (12) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (13) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (14) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (15) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (16) Phosphomevalonate kinase (Genbank No. L77213)
 20. A method for diagnosing whether a test subject suffers from schizophrenia or not, the method comprising the steps of; obtaining mononuclear cell in blood containing ribonucleic acid from said subject and extracting said ribonucleic acid from the blood, immobilizing at least one nucleic acid in said mononuclear cells onto a DNA micro-array or a DNA chip as a probe, the nucleic acid being selected from the group consisting of nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) (containing its fragment and a nucleic acid complementary to the nucleic acid) defining gene(s) exhibiting altered expression by progression of schizophrenia, determining the expression level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia all together using said DNA micro-array or said DNA chip immobilized with the nucleic acid(s), and comparing the determined level(s) with the determined level(s) of said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia in healthy subjects or in schizophrenic patients to determine whether the alteration of said determined level(s) in said test subject is statistically significant or not, thereby diagnosing whether said test subject suffers from schizophrenia or not, wherein said nucleic acid(s) defining gene(s) exhibiting altered expression by occurrence of schizophrenia or said nucleic acid(s) defining gene(s) exhibiting altered expression by progression of schizophrenia is selected from nucleic acid(s) encoding enzyme(s) catalyzing transfer of phosphate group(s) (kinase or phosphatase) and defined by the gene name, the protein name which is a gene product, or the nucleic acid sequence name as described below in (1) to (16) with GenBank No described in brackets. (1) Ndr protein kinase (Genbank No. Z35102) (2) Protein-tyrosine kinase JAK1 (Genbank No. M64174) (3) Inositol polyphosphate 4-phosphatase type I-beta (Genbank No. U96919) (4) AMP-activated protein kinase alpha-1 (Genbank No. AB022017) (5) Protein kinase C Nu (EPK2) (Genbank No. AB015982) (6) MEK kinase (Mekk) (Genbank No. U29671) (7) HSTXK Human tyrosine kinase (TXK) (Genbank No. U07794) (8) Serine/threonine-protein kinase PRP4h (PRP4h) (Genbank No. U48736) (9) Ribosomal protein S6 kinase (ISPK-1) (Genbank No. U08316) (10) Human SNF1-like protein kinase (Genbank No. U57452) (11) SH-PTP3 for protein-tyrosine phosphatase (Genbank No. D13540) (12) Interferon-inducible RNA-dependent protein kinase (Pkr) (Genbank No. U50648) (13) cAMP-dependent protein kinase catalytic subunit type alpha (EC 2.7.1.37) (Genbank No. X07767) (14) PCTAIRE-1 for serine/threonine protein kinase (Genbank No. X66363) (15) Branched chain alpha-ketoacid dehydrogenase kinase precursor (BCKD kinase) (Genbank No. AF026548) (16) Phosphomevalonate kinase (Genbank No. L77213) 